EFFECTS OF THE DIET AND THE CLIMATE IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

FINAL PROGRAM
<table>
<thead>
<tr>
<th>PATRONAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>eular</strong></td>
</tr>
<tr>
<td><strong>SIR</strong></td>
</tr>
<tr>
<td>ERN ReCONNETT</td>
</tr>
<tr>
<td>The University of Genoa</td>
</tr>
<tr>
<td>The Department of internal medicine and medical specialties (DiMI), University of Genoa</td>
</tr>
<tr>
<td>The Region Liguria</td>
</tr>
<tr>
<td>The IRCCS Polyclinic Hospital San Martino Genoa</td>
</tr>
<tr>
<td>The Metropolitan City of Genoa</td>
</tr>
<tr>
<td>The City of Genoa</td>
</tr>
</tbody>
</table>

[www.mediterraneanrheuma.com](http://www.mediterraneanrheuma.com)
From at least 2,000 years the Mediterranean area with the connected Black and Red Sea populations has been the “CRIB” of the culture, science and good life.

What does good life mean?

Good life means an acceptable style of life, even modest but healthy, and of course, it includes good food and good climate! Today, we recognize that, among the multiple risk factors involved in the development of several diseases, environmental and nutritional components play an important role. The rheumatic diseases are among the most common diseases in the general population and the effects of incorrect diets and non-healthy environment/style of life, are recognized as important promoters for their development. A correct diet also represents part of a correct management of the Rheumatic & Musculoskeletal Diseases. Already from the beginning, the Mediterranean Congress of Rheumatology has presented the experiences regarding the characteristics of the Rheumatic Diseases in such an area, and compared their epidemiology among the European countries.

This 2018 edition of the Congress will focus on the effects of diet and climate on the most frequent Rheumatic and Musculoskeletal Diseases, including their early diagnosis and advanced therapies. The Congress topics will be discussed in sequential sessions and will include appropriate presentations on nutritional and environmental factors that will integrate the clinical and drug treatment lectures.

Of course, the participants will have the occasion to taste personally in spring time, the therapeutical effects of the Mediterranean diet and climate “available” for all participants during the Congress that will be held in the Old Harbour of Genoa.

INDEX

Welcome 5

Congress Chairperson and Scientific Board 5

Advisors 6-7

Scientific Program 8-10

Program Overview 11-29

Scientific Program
Thursday 12th April, 2018
Friday 13th April, 2018
Saturday 14th April, 2018

Poster Tours 30-50

Scientific Information 51-53

Abstract book
Guidelines for chairpersons and speakers
Oral Communications and Poster tours
UEMS and ITALIAN CME Accreditation

General Information 54-63

Congress Venue
How to reach the Venue
Congress Centre Parking
Floorplan
Exhibitors
Organizing Secretariat
Opening hours
Registration Information
Networking evening
Social Media

Useful Information 64-65

Admission
Language
Attendance Certificates
Wi-Fi
Coffee break and Lunch
Clearroom
Insurance
No-Smoking
Privacy Disclosure and Publishing of Images
Taxi Discount reserved to attendees

Concomitants Industry-Sponsored SATELLITE LECTURES and SYMPOSIA 66-67

Patients Associations
Acknowledgements

CONGRESS CHAIRPERSON

M. Cutolo Genoa, Italy

On behalf of the Board of the Mediterranean Congress of Rheumatology and of Italian Society of Rheumatology

XVII MEDITERRANEAN CONGRESS SCIENTIFIC BOARD

N. Akkoc Izmir, Turkey
L. Carmona Madrid, Spain
B. Combe Montpellier, France
N. Damjanov Belgrade, Serbia
L. Denisov Moscow, Russia
J.E. Fonseca Lisbon, Portugal
M. Gattorno Genoa, Italy
S. Grazio Zagreb, Croatia
A. Iagnocco Turin, Italy
M. Inanc Istanbul, Turkey
G.D. Kitas Manchester, UK
M. Kouloumas Nicosia, Cyprus
P. Sfikakis Athens, Greece
Y. Shoenfeld Tel Aviv, Israel
S.G. Sokolic Sarajevo, Bosnia and Herzegovina
S.G. Sukkar Genoa, Italy
Z. Szekanecz Debrecen, Hungary
A. Tzioufas Athens, Greece
ADVISORS

INTERNATIONAL ADVISORS

N. Akkoc Izmir, Turkey
S. Aligrutic Podgorica, Montenegro
A. Alunno Cairo, Egypt
B. Anić Zagreb, Croatia
S. Ataman Ankara, Turkey
M. Reda Awaad Giza, Egypt
H. Bassiouni Cairo, Egypt
S. Bombardieri Pisa, Italy
J.W.J. Bijlsma Utrecht, The Netherlands
D. Boumpas Athens, Greece
G.R. Burmester Berlin, Germany
L. Carmona Madrid, Spain
C. Christodoulou Larnaca, Cyprus
B. Coleiro Birkirkara, Malta
B. Combe Montpellier, France
J.A.P. Da Silva Coimbra, Portugal
N. Damjanov Belgrade, Serbia
L. Denisov Moscow, Russia
A. Dinc Çankaya, Turkey
H. Direshkennelı Istanbul, Turkey
A. Doria Padua, Italy
A. El Garf Cairo, Egypt
O. Elkayam Tel Aviv, Israel
K. Elmuntasser Tripoli, Libya
J.E. Fonseca Lisbon, Portugal
M. Gattorno Genoa, Italy
S. Grazio Zagreb, Croatia
A. Gul Istanbul, Turkey
N. Hajaj-Hassouni Rabat, Morocco
I. Holc Maribor, Slovenia
A. Iagnocco Turin, Italy
M. Inanc Istanbul, Turkey
R. Ionescu Bucharest, Romania
L. Kaczak Damascus, Syria
G.D. Kitas Manchester, UK
M. Kouloumas Nicosia, Cyprus
E.J. Kucharz Katowice, Poland
A. Ladjouze Algiers, Algeria
C. Mallia Maida, Malta
X. Mariette Paris, France
A. Martini Genoa, Italy
M. Maturi Cerinic Florence, Italy
I. McInnes Glasgow, UK
G. Minisola Rome, Italy
P. Miossec Lyon, France
S. Misheviska-Percinkova Skopje, Republic of Macedonia
C. Montecucco Pavia, Italy
M. Mosca Pisa, Italy
E. Nasonov Moscow, Russia
E. Nikipherou London, UK
C.H. Opava Huddinge, Sweden
N. Prodanovic Banja Luka, Republic of Srpska - Bosnia Herzegovina
R. Rashkov Sofia, Bulgaria
A. Raveli Genoa, Italy
P. Sarzi Puttini Milan, Italy
J. Sellam Paris, France
P. Sfikakis Athens, Greece
Y. Shoensfeld Tel Aviv, Israel
V. Smith Ghent, Belgium
S. Sokolovic Sarajevo, Bosnia and Herzegovina
R. Straub Regensburg, Germany
S.G. Sukcar Genoa, Italy
Z. Szekanecz Debrecen, Hungary
A. Tafaj Tirana, Albania
M. Tishler Zrlin, Israel
A. Tzioufas Athens, Greece
I. Uthman Beirut, Lebanon
D. Wiek Hünxe, Germany
H. Yazıcı Istanbul, Turkey
D. Vassilopoulos Athens, Greece
L. Zakraoui Tunis, Tunisia

NATIONAL ADVISORS

S. Antonelli Rome, Italy
G. Arioli Mantua, Italy
G. Bajocchi Reggio Emilia, Italy
M. Bentivegna Ragusa, Italy
R. Caporali Pavia, Italy
S. D’Angelo Potenza, Italy
L. Di Matteo Pescara, Italy
M. Galeazzi Siena, Italy
R. Gerl Perugia, Italy
A. Mathieu Cagliari, Italy
I. Olivier Potenza, Italy
L. Quartuccio Udine, Italy
E. Salaffi Ancona, Italy
G. Sebastiani Rome, Italy
L. Sinigaglia Milan, Italy
A. Tincani Brescia, Italy
G. Valesini Rome, Italy

LOCAL ADVISORS

P. Comanducci
Rector University of Genoa

M. Amore
Dean School of Medicine University of Genoa

G. Ucci
CEO of the Polyclinic Hospital San Martino

G. La Valle
Chief Medical Officer of the Polyclinic Hospital San Martino

S. Viale
CEO Health System & Vice President of Liguria Government

M. Bucci
Major of the City of Genoa

S. Balleare
Vice Major of the City of Genoa

MEDICAL TEAM

Division of Rheumatology – DiMI
University of Genoa

A. Sutli
S. Paolino
C. Pizzorni
M. Ghio
B. Ruaro
M. A. Cimmino
## PROGRAM OVERVIEW

### THURSDAY April 12th, 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>PLATEA MAESTRALE ROOM</th>
<th>LEVANTE-PONENTE ROOM</th>
<th>LIBECCIO ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>Opening Registrations and Exhibition •</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>OPENING CEREMONY •</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>LECTURE: The diet in rheumatic autoimmune diseases: a recipe for therapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.40</td>
<td>FIRST SESSION Early Rheumatoid Arthritis</td>
<td>related ORAL COMMUNICATIONS</td>
<td></td>
</tr>
<tr>
<td>15.40-16.10</td>
<td>LECTURE Mediterranean Diet in the 3rd Millennium: Just Prevention or even Therapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.10-16.40</td>
<td>LECTURE Epigenetic Effects of the Mediterranean Diet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40</td>
<td>START THE POSTER EXHIBITION •</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40-17.10</td>
<td>Coffee break (Exhibition Area)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.10-18.20</td>
<td>SECOND SESSION Gouty Arthritis and dismetabolism</td>
<td>related ORAL COMMUNICATIONS</td>
<td></td>
</tr>
<tr>
<td>18.20-18.50</td>
<td>LECTURE Metabolic effects of Glucocorticoids: is there a safe dosage?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

• NO CME ACTIVITY

### FRIDAY April 13th, 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>PLATEA MAESTRALE ROOM</th>
<th>LEVANTE-PONENTE ROOM</th>
<th>LIBECCIO ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.40</td>
<td>THIRD SESSION Osteoarthrits and its management</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PEDIATRIC SESSION Pediatric Rheumatology in the Mediterranean area</td>
</tr>
<tr>
<td>09.40-10.50</td>
<td>FOURTH SESSION Autoinflammatory and Rare Connective Tissue Diseases</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PATIENT SESSION • Pregnancy in RMDs: what the patients would like to know</td>
</tr>
<tr>
<td>10.50-11.20</td>
<td>Coffee break (Exhibition Area)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.20-11.50</td>
<td>Industry - Sponsored SATELLITE LECTURE •</td>
<td>Industry - Sponsored SATELLITE LECTURE •</td>
<td></td>
</tr>
<tr>
<td>11.50-12.20</td>
<td>Industry - Sponsored SATELLITE SYMPOSIUM •</td>
<td>Industry - Sponsored SATELLITE LECTURE •</td>
<td></td>
</tr>
<tr>
<td>12.20-12.50</td>
<td>Industry - Sponsored SATELLITE LECTURE •</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.50-14.00</td>
<td>POSTER TOUR •</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch (Poster Area)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>LECTURE Sun, vitamin D and rheumatic diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>LECTURE Fostering physical activity together with correct nutrition: a successful approach but rarely respected in RMDs</td>
<td></td>
<td>YOUNG PATIENTS AND RHUMATOLIGISTS SESSION • The impact of nutrition and lifestyle on RMDS</td>
</tr>
<tr>
<td>15.00-16.10</td>
<td>FIFTH SESSION From Raynaud’s phenomenon up to systemic sclerosis</td>
<td>related ORAL COMMUNICATIONS</td>
<td></td>
</tr>
<tr>
<td>16.10-16.40</td>
<td>LECTURE Balneotherapy and RMDs: when where and how to choose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40-17.10</td>
<td>Coffee break (Exhibition Area)</td>
<td></td>
<td>MEET THE EXPERT • (Exhibition Area - Booths 5,6)</td>
</tr>
<tr>
<td>17.10-18.30</td>
<td>SIXTH SESSION Systemic Lupus Erythematosus and related syndromes</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PATIENT SESSION • Open Questions to the Physician Nutritionist and to the Dietician</td>
</tr>
</tbody>
</table>
SATURDAY April 14th, 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>PLATEA MAESTRALE ROOM</th>
<th>LEVANTE-PONENTE ROOM</th>
<th>LIBECCIO ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.40</td>
<td>SEVENTH SESSION Spondyloarthritis and Psoriatic Arthritis</td>
<td>related ORAL COMMUNICATIONS</td>
<td>SPECIAL ULTRASOUND SESSION What about pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases?</td>
</tr>
<tr>
<td>09.40-10.50</td>
<td>EIGHTH SESSION Osteoporosis and life style</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PATIENT SESSION • The cold hand: from symptom to diagnosis</td>
</tr>
<tr>
<td>10.50-11.20</td>
<td>Coffee break (Exhibition Area)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.20-12.30</td>
<td>NINTH SESSION Sjögren syndrome today</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PATIENT SESSION • Balneotherapy explained</td>
</tr>
<tr>
<td>12.30-12.45</td>
<td>CLOSING REMARKS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SCIENTIFIC PROGRAM**

We invite all Congress participants to attend the seven Lectures which will be held during Thursday 12 April and Friday 13 April, 2018. Nine Scientific Sessions and related Oral communications will be held over the three days. Other interesting Sessions dedicated to Patients will take place between Friday and Saturday, a Pediatric Session on Friday, as well the SPECIAL Ultrasound Session will run in parallel to the other Scientific Sessions on Saturday. Industry - Sponsored Satellite Lectures and Satellite Symposia will occupy the slots from 11.20 to 12.50 on Friday 13 April, 2018. Poster Exhibition and Tour are planned before afternoon Coffee break on Thursday 12 April and before lunch on Friday 13 April.

**IMPORTANT NOTICE for Scientific Sessions**

We invite all Congress participants to attend the nine Scientific Sessions which will be held during Thursday 12, Friday 13 and Saturday 14 April, 2018 into the “Platea Maestrale” Room. Each Session will focus on the priority themes listed below:

- Epidemiology, nutritional aspects and environmental factors
- The early disease: clinical features and diagnostic tools
- Management: from guidelines up to the last treatment issues
- Management: non pharmacological aspects and unmet needs

**NO CME ACTIVITY**
THURSDAY April 12th, 2018

13.30-14.00 PLATEA MAESTRALE ROOM OPENING CEREMONY
NO CME ACTIVITY
Welcome from Local Academic, Hospital and Government Authorities

14.00-14.30 PLATEA MAESTRALE ROOM LECTURE
The diet in rheumatic autoimmune diseases: a recipe for therapy?
Speaker: Y. Shoenfeld (Tel-Aviv, Israel)
Chair: M. Cutolo (Genoa, Italy)

14.30-15.40 PLATEA MAESTRALE ROOM FIRST SESSION
Early Rheumatoid Arthritis
Speakers:
14.30 Epidemiology, nutritional aspects and environmental factors
I. McInnes (Glasgow, UK)
14.45 The early disease: clinical features and diagnostic tools
G. Burmester (Berlin, Germany)
15.00 Management: from guidelines up to the last treatment issues
B. Combe (Montpellier, France)
15.15 Management: non pharmacological aspects and unmet needs
Z. Szekanecz (Debrecen, Hungary)
Chairs:
G. Burmester (Berlin, Germany), C. Montecucco (Pavia, Italy)

14.30-15.40 LEVANTE-PONENTE ROOM FIRST SESSION
Early Rheumatoid Arthritis
Concomitant Session and related Oral Communications
Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

ORAL COMMUNICATIONS
Speakers:
OC1:1 VACCINATIONS IN INFLAMMATORY ARTHRITIS PATIENTS
S. Khan (Dublin, Ireland)

15.40-16.10 PLATEA MAESTRALE ROOM LECTURE
Mediterranean Diet in the 3rd Millennium: Just Prevention or even Therapy?
Speaker: A. Trichopoulou (Athens, Greece)
Chair: S. G. Sukkar (Genoa, Italy)

16.10-16.40 PLATEA MAESTRALE ROOM LECTURE
Epigenetic Effects of the Mediterranean Diet
Speaker: A. Martinez (Pamplona, Spain)
Chair: S. G. Sukkar (Genoa, Italy)

16.40-17.10 POSTER AREA START THE POSTER EXHIBITION
NO CME ACTIVITY

12-14 April 2018 | Genoa
**THURSDAY April 12th, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.40-17.10</td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>
| 17.10-18.20| **SECOND SESSION**  
**Gouty arthritis and dismetabolism**  
Speakers:  
17.10 Nutritional aspects - including weight loss - for gout: an update from clinical epidemiology  
S.M. Nielsen (Copenhagen, Denmark)  
17.25 The early disease: clinical features and diagnostic tools  
F. Sivera (Alicante, Spain)  
17.40 Management: from guidelines up to the last treatment issues  
P. Richette (Paris, France)  
17.55 Management: non pharmacological aspects and unmet needs  
L. Punzi (Padua, Italy)  
Chairs:  
L. Punzi (Padua, Italy), P. Richette (Paris, France)  |
| 18.20-18.50| **LECTURE**  
Metabolic effects of Glucocorticoids: is there a safe dosage?  
Speaker:  
J.W.J. Bijlsma (Utrecht, The Netherlands)  
Chair:  
M. Cutolo (Genoa, Italy)  |

**ORAL COMMUNICATIONS**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OC2:1</td>
<td><strong>EFFECT OF POLYDATIN AND RESVERATROL ON CRYSTAL INDUCED INFLAMMATION: BENEFICIAL IMPLICATIONS FOR GOUT AND OTHER CRYSTAL-RELATED ARTHROPATHIES</strong></td>
<td>F. Oliviero (Padua, Italy)</td>
</tr>
<tr>
<td>OC2:2</td>
<td><strong>ANALYSIS OF THE EFFICACY OF LOW PURINE DIET IN GOUT PATIENTS</strong></td>
<td>M.S. Eliseev (Moscow, Russia)</td>
</tr>
<tr>
<td>OC2:3</td>
<td><strong>COMBINATION OF LOSARTAN AND ALLOPURINOL IN HYPERTENSIVE PATIENTS WITH HYPERURICEMIA</strong></td>
<td>M. Jordhani (Tirana, Albania)</td>
</tr>
</tbody>
</table>

**OC2:4 ULTRA-LOW DOSE ANTI-INTERLEUKIN1 IN CHRONIC GOUT: A SAFE AND SUCCESSFUL COMBINATION THERAPY WITH LOW DOSE COLCHICINE ANDurate LOWERING AGENTS**  
M. Capasso (Florence, Italy)  
OC2:5 **SEASONAL VARIATION OF JOINT ASPIRATIONS FOR GOUT AND CPPD IN A COHORT OF ARTROPATHIC PATIENTS WITH EFFUSION**  
M.A. Cimmino (Genoa, Italy)  
OC2:6 **GOUT AND METABOLIC SYNDROME**  
N. Zehraoui (Algiers, Algeria)  
Chair - INTRODUCTION:  
S. Grazio (Zagreb, Croatia)  
**LEVANTE-PONENTE ROOM**  
**SECOND SESSION**  
**Gouty arthritis and dismetabolism**  
Concomitant Session and related Oral Communications  
Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion
FRIDAY April 13th, 2018

08.30-09.40  PLATEA MAESTRALE ROOM  THIRD SESSION  Osteoarthritis and its management
Speakers:
- 08.30  Epidemiology, nutritional aspects and environmental factors
   C. Scire (Ferrara, Italy)
- 08.45  The early disease: new aspects on the role of imaging
   A. Iagnocco (Turin, Italy)
- 09.00  Management: from guidelines up to the last treatment issues
   J.Y. Reginster (Liège, Belgium)
- 09.15  Management: non pharmacological aspects and unmet needs
   P. Sarzi-Puttini (Milan, Italy)

08.30-09.40  LEVANTE-PONENTE ROOM  THIRD SESSION  Osteoarthritis and its management
Concomitant Session and related Oral Communications

08.30-09.40  LIBECCIO ROOM  Concomitant Session in the Mediterranean area

08.30-09.40  PLATEA MAESTRALE ROOM  FOURTH SESSION  Autoinflammatory and Rare Connective Tissue Diseases
Speakers:
- 09.40  Autoinflammatory diseases: diagnostic criteria, guidelines and advances
   M. Gattorno (Genoa, Italy)
- 10.00  Focus on familial Mediterranean fever
   H. Lachmann (London, UK)
- 10.25  Focus on Behçet disease
   P. Leccece (Potenza, Italy)
- 10.40  NEWS - Short report on a new European Project- ERN, on Rare Connective Tissue Diseases - ReCONNEX
   M. Mosca (Pisa, Italy)

08.30-09.40  LIBECCIO ROOM  Pediatric Rheumatology in the Mediterranean area
Concomitant Session
Speakers:
- 08.30  Multinational Study on epidemiology, treatment and outcome of children with idiopathic juvenile arthritis
   A. Ravelli (Genoa, Italy)
- 09.00  Longitudinal evaluation of growth and puberty development in pediatric rheumatic diseases
   N. Ruperto (Genoa, Italy)
- 09.30  Discussion
   Chairs:
   A. Martini (Genoa, Italy), A. Ravelli (Genoa, Italy)
FRIDAY April 13th, 2018

09.40-10.50
LEVANTE-PONENTE ROOM
FOURTH SESSION
Autoinflammatory and Rare Connective Tissue Diseases
Concomitant Session and related Oral Communications
Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

ORAL COMMUNICATIONS:
Speakers:

OC4:1 A GENETIC COHORT STUDY TO GENOTYPE SEVERAL INTERLEUKIN GENE POLYMORPHISMS IN A GROUP OF BEHÇET’S SYNDROME PATIENTS LIVING IN THE MEDITERRANEAN AREA
M.C. Padula (Potenza, Italy)

OC4:2 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IN
M.L. Popescu (Bucharest, Romania)

OC4:3 CAN AUTOANTIBODIES PREDICT OUTCOMES OR SURVIVAL IN INTERSTITIAL LUNG DISEASE?: RESULTS FROM A RETROSPECTIVE COHORT STUDY IN GREECE
A. Venetsanopoulou (Athens, Greece)

OC4:4 BIRMINGHAM VASCULITIS ACTIVITY INDEX (BVAS)
A USEFUL TOOL IN DISEASE ACTIVITY IN BEHÇET’S DISEASE
C. Buzatu (Bucharest, Romania)

OC4:5 A SEASONAL ONSET FOR POLYMYALGIA RHEUMATICA?
E. Hysa (Genoa, Italy)

OC4:6 ASSESSMENT OF ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESSMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS
M. Inanc (Istanbul, Turkey)

Chair - INTRODUCTION:
M. Inanc (Istanbul, Turkey)

10.50- 11.20
EXHIBITION AREA
Coffee break

11.20-11.50
PLATEA MAESTRALE ROOM
LEVANTE-PONENTE ROOM
NO CME ACTIVITY
Concomitants Industry
Sponsored SATELLITE LECTURES
see pag. 66-67

11.50-12.50
PLATEA MAESTRALE ROOM
LEVANTE-PONENTE ROOM
NO CME ACTIVITY
Concomitants Industry
Sponsored SATELLITE SYMPOSIA/LECTURES
see pag. 66-67

12.50-14.00
LUNCH AND POSTER AREA
NO CME ACTIVITY
POSTER TOUR
see pag. 30-50

13.00-14.00
LUNCH AND POSTER AREA
Lunch
### FRIDAY April 13th, 2018

#### LECTURE
Sun, vitamin D and rheumatic diseases  
**Speaker:** M. Cutolo (Genoa, Italy)  
**Chair:** G. Minisola (Rome, Italy)

#### YOUNG PATIENTS AND RHEUMATOLOGISTS SESSION
The impact of nutrition and lifestyle on RMDS  
**Concomitant Session**

- **14.00** People’s perceptions on nutritional aspects and rheumatic disease: Completion of the “Truth or myth” questionnaire by the audience  
  - Speaker: E. Philippou (Nicosia, Cyprus - London, UK)
- **14.30** The sun and rheumatic disease: friend or foe?  
  - Speaker: M. Cutolo (Genoa, Italy)
- **15.10** Analysis and sharing of the results of the “Truth or myth” questionnaire at the end of the Session
- **15.20** “Your 5-a-day” VIDEO for a healthy and “joint-friendly” exercise regime that can be undertaken as part of the daily routine
  - Speaker: L. Bacoccoli - Personal trainer Virgin Active Village (Perugia, Italy)

#### WORKSHOP
Problem based cases and discussion  
**Participants will be divided in groups**  
- **M. Kouloumas** (Nicosia, Cyprus), **D. Wiek** (Hünxe, Germany)

#### FIFTH SESSION
From Raynaud’s phenomenon up to Systemic Sclerosis

- **15.00** Epidemiology, nutritional aspects and environmental factors  
  - Speaker: U. Muller-Lardner (Bad Nauheim, Germany)
- **15.15** The early disease: clinical features and diagnostic tools  
  - Speaker: M. Matucci Cerinic (Florence, Italy)
- **15.30** Management: from guidelines up to the last treatment issues  
  - Speaker: C. Denton (London, UK)
- **15.45** Management: non pharmacological aspects and unmet needs  
  - Speaker: O. Distler (Zurich, Switzerland)

- **15.00-16.10** LEVANTE-PONENTE ROOM

**FIFTH SESSION**
From Raynaud’s phenomenon up to Systemic Sclerosis

**Concomitant Session and related Oral Communications**

- **OC5:1** ASSOCIATION OF INTERLEUKIN-17 AND INTERLEUKIN-23 MRNA AND PROTEIN EXPRESSION PROFILES WITH CLINICAL PRESENTATION IN PATIENTS WITH SYSTEMIC SCLEROSIS  
  - Speaker: A. Zekovic (Belgrade, Serbia)

---

**FRIDAY April 13th, 2018**

- **14.00-14.30** PLATEA MAESTRALE ROOM
  - **LECTURE**
    - Sun, vitamin D and rheumatic diseases
    - **Speaker:** M. Cutolo (Genoa, Italy)
    - **Chair:** G. Minisola (Rome, Italy)

- **14.00-16.40** LIBECIO ROOM
  - **YOUNG PATIENTS AND RHEUMATOLOGISTS SESSION**
    - The impact of nutrition and lifestyle on RMDS
      - **Concomitant Session**
        - **14.00** People’s perceptions on nutritional aspects and rheumatic disease: Completion of the “Truth or myth” questionnaire by the audience
          - **Speaker:** E. Philippou (Nicosia, Cyprus - London, UK)
        - **14.30** The sun and rheumatic disease: friend or foe?
          - **Speaker:** M. Cutolo (Genoa, Italy)
        - **15.10** Analysis and sharing of the results of the “Truth or myth” questionnaire at the end of the Session
        - **15.20** “Your 5-a-day” VIDEO for a healthy and “joint-friendly” exercise regime that can be undertaken as part of the daily routine
          - **Speaker:** L. Bacoccoli - Personal trainer Virgin Active Village (Perugia, Italy)
      - **15.30** WORKSHOP
        - Problem based cases and discussion
          - **Participants will be divided in groups**
        - **Speakers:**
          - M. Kouloumas (Nicosia, Cyprus), D. Wiek (Hünxe, Germany)

- **14.30-15.00** PLATEA MAESTRALE ROOM
  - **LECTURE**
    - Fostering physical activity together with correct nutrition: a successful approach but rarely respected in RMDs
    - **Speaker:** G.D. Kitas (Manchester, UK)
    - **Chair:** S. Bombardieri (Pisa, Italy)

- **15.00-16.10** PLATEA MAESTRALE ROOM
  - **FIFTH SESSION**
    - From Raynaud’s phenomenon up to Systemic Sclerosis
      - **Speakers:**
        - **15.00** Epidemiology, nutritional aspects and environmental factors
          - **Speaker:** U. Muller-Lardner (Bad Nauheim, Germany)
        - **15.15** The early disease: clinical features and diagnostic tools
          - **Speaker:** M. Matucci Cerinic (Florence, Italy)
        - **15.30** Management: from guidelines up to the last treatment issues
          - **Speaker:** C. Denton (London, UK)
        - **15.45** Management: non pharmacological aspects and unmet needs
          - **Speaker:** O. Distler (Zurich, Switzerland)

      - **Chairs:**
        - C. Denton (London, UK), V. Smith (Ghent, Belgium)
**FRIDAY April 13th, 2018**

**0C5:2** VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS: CORRELATIONS WITH MULTIPLE CLINICAL PARAMETERS, SEASONAL VARIATIONS AND TREATMENT EFFECTIVENESS IN EUROPEAN SSC PATIENTS  
A.C. Trombetta (Genoa, Italy)

**0C5:3** TYPE 1 INTERFERON INDUCED GENE EXPRESSION IN THE PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS  
N. Vlachogiannis (Athens, Greece)

**0C5:4** CORRELATIONS BETWEEN SKIN BLOOD PERFUSION AND CHOROIDAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS BEFORE AND AFTER A SHORT TIME TREATMENT WITH PROSTACYCLIN ANALOGUE  
A. Soldano (Genoa, Italy)

**0C5:5** RELIABILITY OF SIMPLE CAPILLAROSCOPIC DEFINITIONS TO DESCRIBE CAPILLARY MORPHOLOGY IN RHEUMATIC DISEASES  
A. Vanhaecke (Ghent, Belgium)

**0C5:6** MACITENTAN CONTRASTS THE ACTIVATION OF PROFIBROTIC INTRACELLULAR SIGNALING PATHWAYS INDUCED BY ENDOTHELIN-1 IN PRIMARY CULTURES OF SKIN FIBROBLASTS ISOLATED FROM HEALTHY SUBJECTS  
S. Soldano (Genoa, Italy)

**Chair - INTRODUCTION:**  
A. Soldano (Genoa, Italy)

**16.10-16.40** PLATEA MAESTRALE ROOM  
**LECTURE**  
Balneotherapy and RMDs: when, where and how to choose  
Speaker:  
A. Fioravanti (Siena, Italy)  
Chair:  
T. Bender (Budapest, Hungary)

**16.40-17.10** EXHIBITION AREA  
Coffee break

**16.40-17.10** LEVANTE-PONENTE ROOM  
**SIXTH SESSION**  
Systemic Lupus Erythematosus and related syndromes  
Concomitant Session and related Oral Communications  
Oral Sessions are 70-minute sessions and have 10-minute Chairmen’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

**0C6:1** TRANSCRIPTIONAL REGULATION OF BAFF-R, BCMA AND TACI BY MIR-873 AND MIR-1976 IN JUVENILE SLE  
N.N. Farag (Cairo, Egypt)

**0C6:2** THROMBOSPONDIN-1 IS ELEVATED IN THE PLASMA OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND IS CORRELATED WITH FREE ACTIVE TGF-B1 LEVELS, IL-1B AND IL-17A  
P. Vlachoyiannopoulos (Athens, Greece)

**0C6:3** HYDROXYCHLOROQUINE DOSING: DOES BY IDEAL BODY WEIGHT OR GROSS WEIGHT MAKE A DIFFERENCE?  
H.S.E. Fung (Waco, Texas, USA)

**0C6:4** AVEMAR, A NEW BENZOQUINONE CONTAINING NATURAL PRODUCT IN SLE PATIENTS TREATMENT  
S.G. Sukkar (Genoa, Italy)
FRIDAY April 13th, 2018

OC6:5  ANTIPHOSPHOLIPID SYNDROME: REVIEW OF 52 CASES OF A PORTUGUESE RHEUMATOLOGY DEPARTMENT  
F. Campos Costa (Coimbra, Portugal)

OC6:6  OUTCOME OF ADULT PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS AND JUVENILE IDIOPATHIC ARTHRITIS IN A SINGLE COHORT  
S. Al-Mayouf (Riyadh, Saudi Arabia)

Chair - INTRODUCTION:  
P. Miossec (Lyon, France)

17.10-18.30  LIBECCIO ROOM  
NO CME ACTIVITY

SATURDAY April 14th, 2018

08.30-09.40  PLATEA MAESTRALE ROOM  
SEVENTH SESSION  
Spondyloarthritis and Psoriatic Arthritis  
Speakers:
- 08.30  Epidemiology, nutritional aspects and environmental factors  
  R. Lories (Leuven, Belgium)
- 08.45  The early disease: clinical features and diagnostic tools  
  I.E. Van der Horst-Bruinsma (Amsterdam, The Netherlands)
- 09.00  Management: from guidelines up to the last treatment issues  
  R. Ramonda (Padua, Italy)
- 09.15  Management: non pharmacological aspects and unmet needs  
  F. Ciccia (Palermo, Italy)

Chairs:  
S. D’Angelo (Potenza, Italy), R. Lories (Leuven, Belgium)

08.30-09.40  LEVANTE-PONENTE ROOM  
SEVENTH SESSION  
Spondyloarthritis and Psoriatic Arthritis  
Concomitant Session and related Oral Communications  

Speakers:
- OC7:1  METABOLIC SYNDROME, NON ALCOHOLIC FATTY LIVER DISEASE AND LIVER STIFFNESS IN PSORIATIC ARTHRITIS AND PSORIASIS PATIENTS: A CROSS-SECTIONAL STUDY  
  A. Ortolan (Padua, Italy)
- OC7:2  DO NOT DO RECOMMENDATIONS IN THE MANAGEMENT OF COMORBIDITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. GECOAX PROJECT  
  L. Carmona (Madrid, Spain)
- OC7:3  EFFECT OF FOOD INTAKE AND AMBIENT PARTICULATE AIR POLLUTION ON ANKYLOSING SPONDYLITIS DISEASE ACTIVITY  
  N. Soleimanifar (Tehran, Iran)
- OC7:4  BONE DENSITY IN ALGERIAN PATIENTS WITH ANKYLOSING SPONDYLITIS  
  B. Bengana (Algiers, Algeria)

Chair - INTRODUCTION:  
P. Miossec (Lyon, France)
SATURDAY April 14th, 2018

08.30-09.40 LIBECCIO ROOM

SPECIAL ULTRASOUND SESSION
What about pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases?
Concomitant Session

Speakers:
08.30 Ultrasound in Rheumatology: what, why, when do we assess musculoskeletal tissues and other organs?
A. Iagnocco (Turin, Italy)

08.50 Tips and tricks for pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases
C. Martinoli (Genoa, Italy), B. Ruaro (Genoa, Italy)

09.20 Clinical cases: Ultrasound examinations in patients with nutritional status abnormalities
C. Martinoli (Genoa, Italy), B. Ruaro (Genoa, Italy)

Chair: A. Iagnocco (Turin, Italy)

09.40-10.50 PLATEA MAESTRALE ROOM

EIGHTH SESSION
Osteoporosis and life style

Speakers:
09.40 Epidemiology, nutritional aspects and environmental factors
L. Carmona (Madrid, Spain)

09.55 The early disease: clinical features and diagnostic tools
L. Sinigaglia (Milan, Italy)

10.10 Management: from guidelines up to the last treatment issues
M.L. Brandi (Florence, Italy)

10.25 Management: non pharmacological aspects and unmet needs
J.A.P. Da Silva (Coimbra, Portugal)

Chairs:
M.L. Brandi (Florence, Italy), L. Carmona (Madrid, Spain)
SATURDAY April 14th, 2018

09.40-10.50  LIBECCIO ROOM
PATIENT SESSION
The cold hand: from symptom to diagnosis
SESSIONE DEDICATA AI PAZIENTI
La mano fredda: dal sintomo alla diagnosi
Concomitant Session - Sessione Parallela
Speakers:
The cold hand: the symptom
F. Ingegnoli (Milan, Italy)
The cold hand: the diagnosis
V. Smith (Ghent, Belgium)
Chairs:
V. Smith (Ghent, Belgium), F. Ingegnoli (Milan, Italy)

10.50-11.20  EXHIBITION AREA
Coffee break

11.20-12.30  PLATEA MAESTRALE ROOM
NINTH SESSION
Sjögren syndrome today
Speakers:
11.20  New nutritional aspects as possible risk factors: the role of salt
S. Colafrancesco (Rome, Italy), G. Valesini (Rome, Italy)
11.35  The early disease: clinical features and diagnostic tools
A. Tzioufas (Athens, Greece)
11.50  Management: from guidelines up to the last treatment issues
X. Mariette (Paris, France)
12.10  Management: non pharmacological aspects and unmet needs
L. Quartuccio (Udine, Italy)
Chairs:
X. Mariette (Paris, France), A. Tzioufas (Athens, Greece)

11.20-12.30  LEVANTE-PONENTE ROOM
NINTH SESSION
Sjögren syndrome today
Concomitant Session and related Oral Communications
Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

12.30-12.45  PLATEA MAESTRALE ROOM
CLOSING REMARKS

SATURDAY April 14th, 2018

ORAL COMMUNICATIONS
Speakers:
OC9:1  ERDJ5 FUNCTION IS INVOLVED IN INFLAMMATORY MANIFESTATIONS OF SJÖGREN’S SYNDROME IN THE SALIVARY GLAND
A. Tzioufas (Athens, Greece)
OC9:2  LOW MIR200B-5P LEVELS IN MINOR SALIVARY GLANDS ASSOCIATE WITH LYMPHOMA DEVELOPMENT IN PATIENTS WITH SJÖGREN’S SYNDROME (SS)
A. Tzioufas (Athens, Greece)
OC9:3  SCORING SYSTEMS IN ULTRASOUND OF SALIVARY GLANDS IN SJÖGREN SYNDROME A VIEW OVER TIME
V. Iorgoveanu (Bucharest, Romania)
OC9:4  ULTRASONOGRAPHIC SCORING OF THE MAJOR SALIVARY GLANDS: IS THERE A RELATIONSHIP WITH DISEASE ACTIVITY AND FUNCTIONAL STATUS OF GLANDS
Y. Şahinkaya (Istanbul, Turkey)
OC9:5  SJÖGREN SYNDROME: EVALUATION OF THE DISEASE ACTIVITY USING THE ESSDAI IN 70 PATIENTS
J. Dinis De Freitas (Coimbra, Portugal)
OC9:6  CLINICAL, BIOLOGICAL AND IMMUNOLOGICAL FEATURES OF SJÖGREN SYNDROME: A RETROSPECTIVE MONOCENTRIC TUNISIAN COHORT
M. Kechida (Monastir, Tunisia)

Chair - INTRODUCTION:
N. Damjanov (Belgrade, Serbia)
### POSTER TOUR 1
**Autoinflammatory and Rare Connective Tissue Diseases**
(Posters from n. 001 to 015)

- PT1:001
  **Idiopathic Inflammatory Myopathies: Clinical Characteristics, Survival and Poor Prognostic Factors of 110 Patients from Turkey**
  E. Öğuz, M. Erdügan, B. Artım Esen, A. Gü, L. Ocal, M. İncan (Istanbul, Turkey)

- PT1:002
  **Paradoxical Monoarthritis in the Case Receiving Adalimumab Treatment Due to Hidradenitis Suppurativa**
  S.E. Eşmen, S. Arslan, I. Güney (Konya, Turkey)

- PT1:003
  **Dermatomyositis Associated with Papillary Thyroid Cancer: A Case Report and Review of Literature**
  S. Uğurlu, U. Yılmaz, H. Ozdoğan (Istanbul, Turkey)

- PT1:004
  **Sarcoidosis Following Mycoplasma Pneumoniae Infection**
  I. Sofianos, G. Spiliotis, P. Tzanis, I. Miriokafalitakis (Noula, Greece)

- PT1:005
  **A Diagnostic and Therapeutic Challenge - Behçet's Disease**
  A. Savulescu, L. Ciobică, A. Dumitru, I. Sirbu, L. Panturu, D. Anghel (Bucharest, Romania)

- PT1:006
  **Arthritis – the Substrate of a Rare Dermatologic Disease**
  C. Radu, L. Grosecu (Bucharest, Romania)

- PT1:007
  **Serum Visfatin Levels in Behçet's Disease Patients**
  Z. Özbalcan-Astar, M. Enećik, G. Keskin, Y. Araaslan (Ankara, Turkey)

- PT1:008
  **Lymphoma Case Imitating Takayasu Arteritis**
  G. Kimyon, R. Erdem, E. Micoğulları, R. Mercan (Hatay, Turkey)

- PT1:009
  **Takayasu’s Arteritis: Experience of a Single Tertiary Center**
POSTER TOUR

PT1:010  
A GOOD MIMIC: PMR - IS PMR THE ACCURATE DIAGNOSIS?: A SINGLE- CENTER STUDY  

PT1:011  
SYSTEMIC SARCOIDOSIS ASSOCIATED WITH VIRAL HEPATITIS C: FORTUITOUS ASSOCIATION OR A CAUSAL EFFECT?  
M. Kechida, R. Mesfar, W.B. Mansour, M. Hafsa, S. Hammami, I. Khochtali (Monastir, Tunisia)

PT1:012  
TOCILIZUMAB AS POTENTIAL FIRST OPTION BIOLOGIC THERAPY IN SNITZLER’S SYNDROME  
E.S. Daia-Iliescu, C. Buzatu, R. Ionescu (Bucharest, Romania)

PT1:013  
THE IMPACT OF PROLONGED CORTICOTHERAPY ON DAMAGE PROGRESSION IN PATIENTS WITH BEHÇET’S DISEASE  
E.S. Daia-Iliescu, C.G. Buzatu, I. Saulescu, A. Borangiu, L. Groseanu, V. Bojinca, F. Berghia, D. Predeteanu, R. Ionescu, D. Opris-Belinski (Bucharest, Romania)

PT1:014  
TERTIARY SYPHILIS IN A PATIENT WITH TRAPS UNDER CANAKINUMAB TREATMENT: CASE REPORT  
D. Temiz Karadag, A. Yazici, A. Cefle (Kocaeli, Turkey)

PT1:015  
ADULT STILL’S DISEASE – SERIES OF CLINICAL CASES IN A ROMANIAN REFERENCE CENTER  

POSTER TOUR 2

GOUT AND ARTHRITIS IN DISMETABOLIC CONDITIONS  
Chair: L. Punzi (Padua, Italy)

PT2:016  
MUSCULOSKELETAL ULTRASOUND ABNORMALITIES IN PATIENTS ON DIALYSIS  
R. Decianu, M. Bojinca, C. Capusa, A. Zugravu, V.C. Bojinca (Bucharest, Romania)

PT2:017  
EFFECT OF LOSARTAN IN LOWERING THE LEVEL OF URIC ACID IN PLASMA IN ALBANIAN PATIENTS WITH HYPERURICEMIA AND HYPERTIENSION  
M. Jordhani, D. Ruci, V. Duraj (Tirana, Albania)

POSTER TOUR

PT2:018  
PULMONARY ADENOCARCINOMA PRESENTED WITH ARTHRITIS  
S.E. Esmen, H. Erdogan, E. Kurtipek (Konya, Turkey)

POSTER TOUR 3

OSTEOPOROSIS: THERMAL AND PHARMACOLOGICAL MANAGEMENT  
Chair: T. Bender (Budapest, Hungary)

PT3:019  
PATIENT’S EXPERIENCE OF ALTERED BODY PERCEPTION IN MUSCULOSKELETAL AND RHEUMATIC CONDITIONS  
A. Viceconti, D. Luzzi, E. Camerone, M. Testa (Savona, Italy)

PT3:020  
A LOW FERMENTABLE OLIGO-DI-MONOSACCHARIDES AND POLYOLS DIET IMPROVES SYMPTOMS WITHOUT AFFECTING BODY COMPOSITION AND EXTRACELLULAR BODY WATER IN FIBROMYALGIC PATIENTS WITH IRRITABLE BOWEL SYNDROME  
A. Rossi, M. Bellini, A. Ricciardi, S. Marchi, S. Talarico, M. Mosca, L. Bazzichi (Pisa, Italy)

PT3:021  
CONTROL AND MANIPULATION OF CONTEXTUAL FACTORS IN MUSCULOSKELETAL PAIN MANAGEMENT. A VALID OPPORTUNITY TO ENHANCE THE EFFECTIVENESS OF THE SPECIFIC THERAPY  
G. Rossettini (1), E. Carlino (2), A. Palese (3), M. Testa (1)  
(1) Genoa (Italy), (2) Turin (Italy), (3) Udine (Italy)

PT3:022  
Efficacy and Safety of Intra-Articular Corticosteroid Ultrasound-Guided Injection in Erosive Hand Osteoarthritis  

PT3:023  
COULD HYBRID HYALURONIC ACID REPRESENT A VALID APPROACH TO TREAT RIZOARTHROSIS? A RETROSPECTIVE COMPARATIVE STUDY  
S. Tenti, S. Cheleschi, S. Giannotti, M. Galeazzi, N.A. Giordano, A. Fioravanti (Siena, Italy)

PT3:024  
PAIN IN KNEE: MORE THAN JUST WEAR AND TEAR DUE TO OSTEOARTHRITIS  
M. Parvu, G. Novac, A. Nistor, I. Scheip, S. Voidazan (Tg Mures, Romania)

PT3:025  
INTRA-ARTICULAR HYALURONIC ACID FOR KNEE OSTEOARTHRITIS: TWO YEARS EFFICACY OF A QUARTERLY REGIMEN  
F. Galluccio, M. Capassoni, M. Matsuuci Cerinio (Florence, Italy)
EFFECTS OF THE DIET AND THE CLIMATE IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

MEDITERRANEAN CONGRESS OF

POSTER TOUR

PT3:026
THE EFFECTIVENESS OF SAFFRON PILL IN TREATMENT OF OSTEOARTHRITIS: A RANDOMIZED, DOUBLE-BLIND CONTROLLED TRIAL
M. Firoozabadi (1), M. Aghei (1), S.Z. Mirfeizi (2), G.R. Roshandel (3), N. AbdolAhi (1)
(1) Golestan (Iran), (2) Razavi Khorasan (Iran), (3) Gorgan (Iran)

PT3:027
BALNEOTHERAPY IN KNEE OSTEOARTHRITIS: A COST/EFFECTIVENESS ANALYSIS ALONGSIDE AN ITALIAN RANDOMIZED CONTROLLED CLINICAL TRIAL
A. Fioravanti (1), O. Ciani (1), S. Tenti (1), C. Giannitti (1), M. Meregaglia (1), M. Galeazzi (1)
(1) Siena (Italy), (2) Milan (Italy)

POSTER TOUR 4
OSTEOPOROSIS/OSTEOMALACIA AND MALABSORPTION
Chair: S. Sokolović (Sarajevo, Bosnia and Herzegovina)

PT4:028
VITAMIN D DEFICIENCY IN THE ACUTE CARE UNIT. IS IT RELATED TO SURVIVAL?
I. Kostoglou-Athanassiou (1), E. Pantazi (1), I. Mavropoulos (1), O. Skioti (1), D. Kousouris (1), S. Kontogiannis (1), P. Athanassiou (1)
(1) Athens (Greece), (2) Thessaloniki (Greece)

PT4:029
VITAMIN D DEFICIENCY AND OSTEOMALACIA IN ACUTE ILY PATIENTS AFTER SURGICAL TREATMENT FOR COLON CANCER
P. Athanassiou (1), L. Athanassiou (1), P. Potamousi (1), R. Alevizou (1), M. Digalakis (1), I. Kostoglou-Athanassiou (1)
(1) Thessaloniki (Greece), (2) Athens (Greece)

PT4:030
EFFECTIVENESS OF DENOSUMAB IN ADJUSTMENT OF OSTEOPOROSIS TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
R. Yatsyshyn, O. Shtefiuk, I. Popadynets, G. Kuryliv, I. Stoika
(Ivano-Frankivsk, Ukraine)

PT4:031
EVALUATION OF EFFECTS OF ADAPTED PHYSICAL ACTIVITY PROGRAM ON FUNCTIONAL ORGANIC INDEXES AND BMD IN OSTEOPOROTIC PATIENTS TREATED WITH DENOSUMAB
A. Romeo, C. Baiano
(Syracuse, Italy)

PT4:032
BREAST CANCER AND SKELETAL HEALTH: EVALUATION OF BONE MINERAL DENSITY AND FRACTURE RISK
S. Paolino, E. Gotelli, V. Tomatis, R. Murialdo, L. Tixi, R. Gonella, A. Ballestrero, M. Cuto (Genoa, Italy)

PT4:033
THE 3-YEAR EFFICACY OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY OF LUMBAR SPINE AND FEMORAL NECK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
E. Mole, K. Zoupidou, A. Alexoudis, D. Moshou, O. Prelorentzos, S. Gazi (Kifisia, Greece)

PT4:034
TENDENCIES OF BONE MINERAL DENSITY IN YOUNG ADULTS AND THE INFLUENCE OF DIET AND OTHER LIFESTYLE HABITS
I. Badea (Bucharest, Romania)

POSTER TOUR 5
PSORIATIC ARTHRITIS / SPONDOARTHRITIS
Chair: R. Ramonda (Padua, Italy)

PT5:035
THE PREVALENCE AND COMORBIDITIES ASSOCIATED WITH PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS: AN OBSERVATIONAL COHORT STUDY
A. Abdalla (1), M. Abd El Haleem (2)
(1) Aswan (Egypt), (2) Benha (Egypt)

PT5:036
ASSOCIATION BETWEEN LIVER STEATOSIS, METABOLIC PROFILE AND RHEUMATOLOGIC DISEASES: A SINGLE CENTER STUDY
C. Bruno, R. Grembiale, L. Abenavoli, S. Naty (Catanzaro, Italy)

PT5:037
OBESITY AND RESPONSE TO TNF INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS – DATA FROM A ROMANIAN COHORT
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, C. Iordache, I. Esanu, R. Chirieac (Iasi, Romania)

PT5:038
PREVALENCE OF COMORBIDITIES IN PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY

PT5:039
HYPERURICEMIA IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS
(Bucharest, Romania)

PT5:040
METABOLIC SYNDROME AND ANKYLOSING SPONDYLITIS IN ALGERIAN PEOPLE
N.C. Zehraoui, R. Benaziez-Boutalebi, O. Cheikh, M. Berkache, M. A. Iticene, C. Dahou-Makhloufi
(Algiers, Algeria)
PT5:041
PARADOXICAL INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHROPATHIES TREATED WITH ANTI-TNF AGENTS
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, R. Chirieac (Iasi, Romania)

PT5:042
ASAS HEALTH INDEX AND ENVIRONMENTAL FACTORS (ASAS HI/EF) IN PATIENTS WITHankylosing spondylitis and concomitant fibromyalgia
I. Shapoval, M. Stanislaschuk, K. Zaichko (Vinnytsya, Ukraine)

PT5:043
DNA METHYLOME AND SERUM PROTEOME ANALYSES IDENTIFY NEW BIOMARKERS OF psoriasis and psoriatic arthritis in monozygotic twins
M. Meroni[1], A. Ceribelli[1], E.M. Paraboschi[1], N. Isaiovic[1], E. Generali[1], M. Robusto[1], M. De Santis[1], G. Cardamone[1], F. Sacrini[1], A. Costanzo[1], S. Duga[1], C. Selmi[2]

PT5:044
PROTEIN LEVELS AND AUTOANTIBODIES AGAINST LL37 AND IFI16 NUCLEIC ACID SENSORS IN psoriatic arthritis
M. Meroni[1], N. Isaiovic[1], M. De Santis[1], A. Ceribelli[1], E. Generali[1], L. Altamore[1], G. Sabatino[1], P. Rovero[1], A. M. Papini[1], V. Caneparo[1], S. Landolfi[1], M. Gariglio[1], M. De Andrea[1], C. Selmi[1,2]

PT5:045
THE INFLUENCE OF SMOKING ON RESPONSE TO ANTI TNF THERAPY IN PATIENTS WITH ANKYLosing spondylitis
D. Anghel, C. Jurcut, A. Anghel, M. M. Negru, A. E. Savulescu, L. Panturu (Bucharest, Romania)

PT5:046
FACTORS ASSOCIATED WITH STOPPING BIOLOGICAL TREATMENT IN PATIENTS WITH ANKYLosing spondylitis
G. Iftimie, C. Buta, L. Grosecu, R. Ionescu, D. Opris-Belinski (Bucharest, Romania)

PT5:047
ULTRASONOGRAPHIC CHANGES OF ASYMMETRIC ANTERIOR CHEST WALL JOINTS IN ANKYLosing spondylitis and their relation to chest expansion
F. Hassan, M. Mortada, A. Bakry, A. Elsammanak (Zagazig, Egypt)

PT5:048
GLOBAL HEALTH ASSESSMENT BY RHEUMATOLOGIST AND BY PATIENT IN psoriatic arthritis, rheumatoid arthritis and osteoarthritis
F. Grubacic, H. Skala Kavangh, I. Doko, S. Grazi[c] (Zagreb, Croatia)

PT5:049
TWO-YEARS SURVIVAL OF USTEKINUMAB IN psoriatic arthritis patients

PT5:050
PROMPT CLINICAL RESPONSE TO SECUKINUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: REAL-LIFE OBSERVATIONAL DATA FROM THREE ITALIAN REFERRAL CENTERS
S. Gentileschi[1], A. Vitale[2], D. Rigante[2], G. Lopalco[3], G. Emmi[4], J. Orlando[5], G. Di Scala[6], J. Sota[7], C. Fabiani[7], B. Frediani[7], M. Galeazzi[7], G. Lapadula[7], F. Iannone[8], L. Cantarini[8]

PT5:051
THE ASSESSMENT OF THE RELATION BETWEEN SERUM URIC ACID LEVEL AND DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS
I.H. Dursun, F. Cosan, B. Yilmazer, A. Cefle (Kocaeli, Turkey)

PT5:052
OBESITY INTERACTS WITH RESPONSE AND INCREASES THE RISK OF HYPERTRANSAMINEMINA IN PSORIATIC ARTHRITIS
L. Carmona[1], E. Galíndez[2]

PT6A:053
RITUXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN A PATIENT WITH COMORBIDITY: CHONDROSARCOMA/OSTEOSARCOMA OF THE Cavernous Sinus
M. Barisic, L. Simetic, D. Hercog, B. Anic (Zagreb, Croatia)

PT6A:054
PERIPHERAL BLOOD B-CELL SUBSETS IN PATIENTS WITH VERY EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS
A. Ardieva, A. Aleksankin, T. Popkova, E. Suponitskaya, E. Nasonov (Moscow, Russia)

PT6A:055
IS IT POSSIBLE TO REPLACE THE RADIOLOGICAL ASSESSMENT OF DESTRUCTIVE CHANGES IN RHEUMATOID ARTHRITIS (RA) BY ULTRASONOGRAPHS (US)?
O. Aleseeva, A. Smirnov, A. Volkov, E. Nasonov (Moscow, Russia)
PT6A:056
EDUCATING PEOPLE WITH RMDS TO FOLLOW A CORRECT DIET: AN INNOVATIVE 3 STEPS PROJECT
U.G. Viora, S. Severoni, S. Tonolo (Rome, Italy)

PT6A:057
FOLIC ACID SUPPLEMENTATION REDUCES METHOTREXATE EFFICACY AND DELAY CLINICAL IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS
A. Sulli, S. Paolino, C. Pizzorni, E. Alessandri, M. Patanè, M. Ghio, M. Cutolo (Genoa, Italy)

PT6A:058
CLINICAL AND ECONOMIC VALUE OF SERUM AUTOANTIBODIES MULTI-TESTING IN RHEUMATOID ARTHRITIS IN THE MEDITERRANEAN AREA
B. Mascialino (1), S. Swiniarski (2), I. Gehring (2), M. Poorafshar (1)
(1) Uppsala (Sweden), (2) Freiburg (Germany)

PT6A:059
CAN DIET MODIFY RISK AND COURSE OF INFLAMMATION AND MALIGNANCY?
E. Kucharz (Katowice, Poland)

PT6A:060
TRADITIONAL TYPE 2 DIABETES RISK FACTORS AND INSULIN RESISTANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS
L. Kondrateva, T. Popkova (Moscow, Russia)

PT6A:061
THE EFFECT OF TOCILIZUMAB THERAPY ON THE BODY MASS INDEX, WAIST AND HIP CIRCUMFERENCE, LIPIDS PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS
E. Gerasimova, T. Popkova, A. Martinova, E. Zhilyaev, G. Lukina (Moscow, Russia)

PT6A:062
SMOKING AND RHEUMATOID ARTHRITIS
D. Dusa, M. Suta (Constanta, Romania)

PT6A:064
A PATIENT PRESENTING WITH JAW PAIN. DIAGNOSIS, TREATMENT AND REVIEW OF THE LITERATURE
C. Christodoulou (Larnaca – Nicosia, Cyprus)

PT6A:065
THE INFLUENCE OF ABACTCEPT ON BIOMARKERS LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS

PT6A:066
THE INFLUENCE OF SMOKING ON CLINICAL RESPONSE TO ETANERCEPT THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
S. Zivojinovic, M. Bukilica, N. Damjanov (Belgrade, Serbia)

PT6A:067
SECONDARY SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS
R. Yatsyshyn, I. Stoika (Ivano-Frankivsk, Ukraine)

PT6A:068
DIET IN CHILDREN WITH IJA: AN INNOVATIVE 4 STEPS PROJECT TO OVERCOME CULTURAL BARRIERS
U.G. Viora, G. Mascarino, S. Tonolo (Rome, Italy)

PT6A:069
27-YEARS OLD FEMALE WITH POLYARTHRITIS, DRYNESS SYNDROME AND ACUTE LOSS OF VISUAL ACUITY
P. Tzanis, I. Sofianos, G. Spiliotis, I. Myriokefalitakis (Voula, Greece)

PT6A:070
RHEUMATOID ARTHRITIS PATIENT WITH MASS ON THE ANTERIOR CHEST WALL
Ö. Soysal Gündüz, G. Gunduz, D. Demir (Manisa, Turkey)

PT6A:071
A STRUCTURED PROTOCOL FOR THE EVALUATION OF CARDIO-VASCULAR RISK IN ARTHRITIS PATIENTS
F. Sivera, N. Alberola, G. Albert, C. Fernandez-Carballido, R. Martin, T. Pedraz (Elda, Spain)

PT6A:072
EFFECTS OF MEDITERRANEAN DIET AND PHYSICAL THERAPY IN EARLY STAGES OF OligoARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
L.M. Ailioaie, C. Ailioaie (Iasi, Romania)

PT6A:073
CONSTRUCT VALIDITY, REPRODUCIBILITY AND FEASIBILITY OF THE PRO-THERMOMETER-5ITEM (5T-PROS) IN THE EVALUATION OF THE HEALTH STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHITIS AND FIBROMYALGIA
F. Salaffi, S. Farah, M. Di Carlo, M. Carotti (Ancona, Italy)
PT6B:074
CONSTRUCT VALIDITY AND INTERPRETABILITY OF THE QUICKDASH IN THE ASSESSMENT OF RHEUMATOID ARTHRITIS HAND DISABILITY
F. Salaffi, S. Farah, M. Di Carlo, M. Carotti (Ancona, Italy)

PT6B:075
EVOLUTION OF PAIN IN RHEUMATOID ARTHRITIS TREATED WITH ANTI-INTERLEUKIN 6
N. Bldi, N. Saidi, R. Benaziez, N. Zehraoui, M.A. Itticene, F. Mechid, C. Dahou-Makhloufi
(Algiers, Algeria)

PT6B:076
PATIENTS’ SATISFACTION WITH HEALTH CARE PROVIDED IN AN OUTPATIENT CLINIC FOR RHEUMATOLOGY: RESULTS OF A QUESTIONNAIRE STUDY OF SPECIFIC ASPECTS OF CARE
D. Cubelic [i], M. Reihl [ii], M. Mayer [i], B. Anic [i]
[i] Zagreb (Croatia), [ii] Vukovar (Croatia)

PT6B:077
PREDICTIVE FACTORS OF EVOLUTION OF EARLY INFLAMMATORY ARTHRITIS TO RHEUMATOID ARTHRITIS
F. Rahal, R. Chetouane, S. Haid, N. Brahimi, A. Ladjouze-Rezig, F. Hanni (Algiers, Algeria)

PT6B:078
ULTRASONOGRAPHIC FINDINGS OF HIP JOINTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
S. Prodanovic, G. Radunovic, N. Damjanov (Belgrade, Serbia)

PT6B:080
RITUXIMAB: COMPARISON CLINICAL AND ANTI-DESTRUCTIVE EFFECTS AND B-CELL COUNT IN RHEUMATOID ARTHRITIS PATIENTS.
A. Pivano, G. Lukina, Y. Sigidin, A. Smirnov, S. Glukhova, A. Kuznetsova, K. Kuzikytas, E. Nasonov (Moscow, Russia)

PT6B:081
EFFECT OF A DYNAMIC EXERCISE PROGRAM IN COMBINATION WITH A MEDITERRANEAN DIET IN WEIGHT AND HANDGRIIP STRENGTH IN WOMEN WITH RHEUMATOID ARTHRITIS

PT6B:082
RHEUMATOID ARTHRITIS: FREQUENCY AND INFLUENCE OF TOBACCO AND BODY MASS INDEX (BMI) IN THE ACTIVITY OF THE DISEASE

PT6B:083
PERIODONTITIS IN EARLY RHEUMATOID ARTHRITIS: CASE-CONTROL STUDY
F. Mechid, C. Dahou, M. Moddod, S. Salah, S. Merad (Algiers, Algeria)

PT6B:084
CONTRIBUTION OF VITAMIN D RECEPTOR FOKI GENE POLYMORPHISM ON DISEASE SEVERITY AND LONG TERM DISEASE OUTCOME IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)
D. Lazarevic [ii], J. Vojinovic [i], G. Susac [i], J. Basic [i], J. Milenkovic [i]
[ii] Niš (Serbia), [i] Belgrade (Serbia)

PT6B:085
IS PROTEIN C REACTIVE RELATED TO METABOLIC SYNDROME IN RHUMATOID ARTHRITIS?
M. Kechida [ii], N. Lorenzo Vilalba [ii], R. Mesfar [i], Y. Alvarado Funes [i], R. Klii [ii], S. Hammami [ii], I. Khochtali [i]
[ii] Monastir (Tunisia), [i] Liège (Belgium)

PT6B:086
THE EFFICACY AND SAFETY OF METHOTREXATE IN A DOSE 25 MG PER WEEK AND MORE IN PATIENTS WITH RHEUMATOID ARTHRITIS.
G. Gridneva (Moscow, Russia)

PT6C:087
IMPAIRED WOUND HEALING DUE TO LEFLUNOMIDE USE IN PATIENTS WITH RHEUMATOID ARTHRITIS
V. Gerdan (Izmir, Turkey)

PT6C:088
THE EFFECT OF GENDER ON ANEMIA FREQUENCY IN RHEUMATOID ARTHRITIS
S.E. Esmen, A. Tekinalp (Konya, Turkey)

PT6C:089
THE RELATIONSHIP OF ANEMIA FREQUENCY AND DISEASE ACTIVITY IN THE PATIENTS WITH RHEUMATOID ARTHRITIS
S.E. Esmen, A. Tekinalp (Konya, Turkey)

PT6C:090
KIR GENE DISTRIBUTION IN TURKISH PATIENTS WITH RHEUMATOID ARTHRITIS
E. Erken, F. Kocabas, O. Ozturk, S. Dinkci, N. Yilmaz (Adana, Turkey)

PT6C:091
FACTORS CONTRIBUTING TO DISABILITY IN RHEUMATOID ARTHRITIS PATIENTS: AN EGYPTIAN MULTICENTER STUDY
M. Eissa [i], M. Hammad [ii], G. Dawa [ii]
[i] Cairo (Egypt), [ii] Zagazig (Egypt)
POSTER TOUR

PT6C:092
NEW DYNAMOMETRIC PARAMETERS IN EVALUATION OF HAND FUNCTION IN RHEUMATOID ARTHRITIS BASED ON DYNAMIC MEASUREMENTS– A PILOT EVALUATION STUDY
I. Doko, A. Dubravč, J. Michieli, B. Medved Roga, S. Grazio (Zagreb, Croatia)

PT6C:093
PYODERMA GANGRENOSUM: A PARADOXICAL SIDE EFFECT IN A RHEUMATOID ARTHRITIS PATIENT TREATED WITH GOLIMUMUM
T. Dimitroulas, D.M. Manoli, A. Skalkov, V. Douros, K. Petidis, S. Vakirtis, A. Pyrpasoupolou (Thessaloniki, Greece)

PT6C:094
METHOTREXATE INTOXICATION: BEYOND THE ADVERSE EVENTS
E. Daikiili, B.N. Coskun, B. Yagit, S. Ermurat, A.N. Tufan, Y. Pehlivan (Bursa, Turkey)

PT6C:095
ORAL STATUS IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS OF AN ALGERIAN STUDY

PT6C:096
LOW RHEUMATOID ARTHRITIS PREVALENCE IN ALGIERIA: A MEDITERRANEAN SINGULARITY?

PT6C:097
IMMUNOCORRECTIVE THERAPY IN THE COMPLEX TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, H. Khurtsaleva, H. Kolupaeva (Minsk, Belarus)

PT6C:098
CLINICAL AND ULTRASOUND CONCORDANCE IN RHEUMATOID ARTHRITIS
R. Chetouane (Algiers, Algeria)

PT6C:099
A PRACTICAL CONSENSUAL APPROACH TO MANAGE COMORBIDITY IN RHEUMATOID ARTHRITIS
L. Carmona, S. Castañeda (Madrid, Spain)

PT6C:100
SAFETY AND EFFICACY OF A TRIVALENT, INACTIVATED INFLUENZA VACCINE IN PATIENTS WITH RHEUMATIC DISEASES (PRELIMINARY RESULTS)
D. Bukhanova, B. Belov, G. Tarasova, M. Cherkasova, S. Erdesz, T. Dubinina, N. Demidova, A. Volkov (Moscow, Russia)

PT6C:101
ACUTE LIVER FAILURE AS REACTION TO TOCILIZUMAB THERAPY
M. Bogojivic, N. Miketic, E. Strijic (Podgorica, Montenegro)

PT6C:102
FACTORS ASSOCIATED WITH INTOLERANCE OF METHOTREXATE IN PATIENTS WITH INFLAMMATORY JOINT DISEASE
B. Bengana, A. Boukabous, N. Bahaz, S. Mostefai, S. Lefkir-Tafiani (Algiers, Algeria)

PT6C:103
SCREENING FOR SKIN MALIGNANCIES AMONG PATIENTS TREATED WITH BIOLOGICS – PILOT STUDY FROM A SINGLE CROATIAN RHEUMATOLOGY CENTER
M. Barcic, R. Jurakic Toncic, B. Marinovic, B. Anic (Zagreb, Croatia)

POSTER TOUR 7
SJÖGREN SYNDROME AND ENDOCRINE RHEUMATIC DISORDERS
Chair: G.D. Kitas (Paris, France)

PT7:104
IS SALIVARY GLAND INHOMOGENEITY AN EARLY ULTRASONOGRAPHIC SIGN IN SJÖGREN SYNDROME?
V. Iorgoveanu, D. Mazilu, V. Bojinca, L. Groseanu, D. Belinski, A. Balanescu, C. Constantinescu, V. Vlad, I. Saulescu, M. Gheorghe, D. Predeteanu, R. Ionescu (Bucharest, Romania)

PT7:105
RENAL INVOLVEMENT IN PRIMARY SJÖGREN SYNDROME-A CASE REPORT
L. Brites, J. Freitas, M. Luis, J. Rovisco, M. Santiago, C. Duarte, A. Malcata, F. Costa (Coimbra, Portugal)

PT7:106
ANCA-ASSOCIATED VASCULITIS IN A PATIENT WITH PRIMARY SJÖGREN SYNDROME
P. Athanassiou, D. Pantelidis, C. Gerodimos (Thessaloniki, Greece)

PT7:107
SECONDARY SJÖGREN SYNDROME: CLINICAL FEATURES AND PREDICTIVE FACTORS
M. Kechida (1), N. Lorenzo Vilalba (2), A. Alaya (1), R. Mesfar (1), R. Kli (1), S. Hammami (1), J. Khochtali (1)
(1) Monastir (Tunisia), (2) Liege (Belgium)

PT7:108
VITAMIN D STATUS IN A LUCANIAN COHORT OF ANTI-DFS70/LEDGF POSITIVE ADULT SUBJECTS
T. Carbone, G. Tramontano, M. Gilo, M.C. Padula, A. Padula, V. Pafundi, S. D’Angelo (Potenza, Italy)

PT7:109
SYSTEMIC SCLEROSIS IN ELDERLY: A RETROSPECTIVE BI-CENTRIC COHORT
M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (1), R. Kli (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Liege (Belgium)
EFFECTS OF THE DIET AND THE CLIMATE IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

MEDITERRANEAN CONGRESS OF

POSTER TOUR POSTER TOUR

PT8A:117
CLINICAL MANIFESTATIONS AND LABORATORY MARKERS THAT IMPACT LONG TERM DAMAGE IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME


PT8A:118
THE IMPACT OF THE PLACE OF RESIDENCE ON SYSTEMIC LUPUS ERYTHEMATOSUS

I. Gergianaki (1), C. Adamichou (1), G. Spyroy (1), D. Boumpas (1,2,3), P. Sidiropoulos (1), G. Bertsias (1)

(1) Irakleio (Greece), (2) Athens (Greece), (3) Nikosia (Cyprus)

PT8A:119
OUTCOME OF CHILDHOOD LUPUS NEPHRITIS IN SAUDI CHILDREN

S. Al-Mayouf, A AlAmeer, A Alfattani, A Alsonbul (Riyadh, Saudi Arabia)

PT8A:120
PHARMACEUTICAL DISRUPTION OF B2GPI CXCL4 COMPLEX USING COMPUTATIONALLY DESIGNED OLIGOPEPTIDES

M. Patsouras, E. Papakonstantinou, E. Eliopoulos, P. Vlachoyiannopoulos (Athens, Greece)

PT8A:121
WHOLE TRANSCRIPTOME ANALYSIS OF APL TREATED HUVECS MAPS PROINFLAMMATORY AND PROCOAGULANT PATHWAYS

M. Patsouras, P. Karagianni, S. Foutas, E. Alexopoulou, M. Aggelopoulos, D. Thanos, A. Tzioufas, P. Vlachoyiannopoulos (Athens, Greece)

POSTER TOUR

POSTER TOUR

SYSTEMIC LUPUS ERYTHEMATOSUS / ANTIPHOSPHOLIPID SYNDROME

Chair: A. Doria (Padua, Italy)

PT8A:110
INFECTIOUS COMORBIDITIES IN SLE PATIENTS - CLINICAL CASES IN A ROMANIAN REFERENCE CENTER


PT8A:111
GANGRENE IN SYSTEMIC LUPUS ERYTHEMATOSUS : ABOUT TWO CASES

N. Bledi, N. Zehraoui, R. Atamane, C. Dahou (Algiers, Algeria)

PT8A:112
VITAMIN D DEFICIENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATIONSHIP WITH DISEASE ACTIVITY

L. Athanassiiou (1), I. Kostoglou-Athanassiiou (1), C. Katsavouni (1), A. Tzanavari (1), A. Koteli (1), C. Mavragani (1), M. Koutsiliaris (1), P. Athanassiiou (1)

(1) Athens (Greece), (2) Thessaloniki (Greece)

PT8A:113
NAILFOLD CAPILLAROSCOPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL


(1) Genoa (Italy), (2) Ghent (Belgium), (3) Milan (Italy), (4) Bad-Nauheim (Germany), (5) Rome (Italy)

PT8A:114
EVALUATION OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC LUPUS ERYTHEMATOSUS AND PRIMARY RAYNAUD’S PHENOMENON PATIENTS.

B. Ruaro (1), A. Sulli (1), C. Pizzorni (1), S. Paolino (1), V. Smith (2), M. Pendolino (1), M. Cutolo (1)

(1) Genoa (Italy), (2) Ghent (Belgium)

PT8A:115
EXPRESSION OF TNF-A AND IL-6 IN PATIENTS WITH UNTREATED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RELATIONSHIP WITH DISEASE ACTIVITY

T. Panafidina, T. Popkova, E. Aleksandrova (Moscow, Russia)

PT8A:116
INCREASED CARDIOVASCULAR AND METABOLIC COMORBIDITIES IN ROMANIAN LUPUS PATIENTS

D. Opris-Belinski, A. Balanescu, C. Branescu, D. Predeteanu, V. Bojicu, I. Saulescu, L. Grosseanu, C. Nicolae, C. Constantinescu, R. Ionescu (Bucharest, Romania)

POSTER TOUR

SYSTEMIC LUPUS ERYTHEMATOSUS / ANTIPHOSPHOLIPID SYNDROME

Chair: A. Doria (Padua, Italy)

PT8B:122
IMPACT OF SEVERE ORGANIC CNS INVOLVEMENT IN COGNITIVE FUNCTION IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS, WITH THE ACR-SLE BATTERY

C. Golemati, E. Kampylafka, C. Papageorgiou, P. Vlachoyiannopoulos, A Tzioufas (Athens, Greece)

PT8B:123
ANTI-PHOSPHOLIPID ANTIBODIES ARE INDEPENDENTLY ASSOCIATED WITH ATHEROSCLEROSIS IN THE GENERAL POPULATION

M. Meroni (1), C. Selmi (1,2), E. Generali, M. De Santis, P.M. Battezzati, A. Ceribelli, M. Zuin (2)

(1) Rozzano (Italy), (2) Milan (Italy)

PT8B:124
SHOULD WE SCREEN FOR ATHEROSCLEROSIS AT AN EARLIER AGE FOR WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS?

I. Saulescu, A. Borangiu, D. Opris-Belinski, S. Daia-Iliescu, L. Groseanu, R. Ionescu (Bucharest, Romania)
PT8B:125
LUPUS NEPHRITIS: SERIES OF 12 CLINICAL CASES IN A ROMANIAN REFERENCE CENTER
M.L. Popescu, D. Predeteanu, V. Bojinca, L. Groseau, D. Opris Belinski, C. Constantinescu, D. Mazilu, R. Ionescu (Bucharest, Romania)

PT8B:126
FEATURES ASSOCIATED WITH OUT-OF-HOSPITAL DEATH IN A GROUP OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DECEASED OVER A 10-YEAR PERIOD
I. Padjen, M. Erceg, M. Cerovec, M. Mayer, R. Stevanovic, B. Anic (Zagreb, Croatia)

PT8B:127
FEMALE LUPUS PATIENT OPTIONS REGARDING TREATMENT AND NEGATIVE PREGNANCY OUTCOME
D. Opris Belinski (1), C. Ancuta (1), M. Pirvu (1), A. Balanescu (1), V. Bojinca (1), I. Saulescu (1), D. Mazilu (1), R. Ionescu (1)
(1) Bucharest (Romania), (1) Iasi (Romania), (1) Tg Mures (Romania)

PT8B:128
AUTOANTIBODIES AS BIOMARKERS IN THE PREDICTION OF CLINICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
A.N. Nistor, I. Scheie, M. Parvu (Tg Mures, Romania)

PT8B:129
LUPUS NEPHRITIS: CLINICAL MANIFESTATIONS AND RISK FACTORS
M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (2), Y. Alvarado Funes (2), R. Kli (1), S. Hammami (1), L. Khochtali (1)
(1) Monastir (Tunisia), (2) Belgium (Belgium)

PT8B:130
TWO CASES OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN PATIENTS WITH SLE
Z. Kardum, V. Prus, J. Milas Ahic (Osijek, Croatia)

PT8B:132
PITYRIASIS LICHENOIDES ET VARIOLIFORMIS ACUTA (PLEVA) DEVELOPING DEPENDING ON THE USE OF HYDROXYCHLOROQUINE
S.E. Esmen, S. Arslan (Konya, Turkey)

PT8B:133
LUPUS PREGNANCY: ACHIEVEMENTS AND OPEN ISSUES IN THE MULTIDISCIPLINARY MANAGEMENT
F. Crisafulli (1), L. Andreoli (1), L. Antolini (1), G. Parma (1), C. Benigna (1), A. Lojacono (1), S. Zatti (1), V. Cappa (1), S. Calza (1), A. Tincani (1)
(1) Brescia (Italy), (1) Napoli (Italy)

PT9A:134
MACROVASCULAR IMPAIRMENT AND LIPID PROFILE IN SYSTEMIC SCLEROSIS PATIENTS
S. Paolini, E. Gotelli, V. Tomatis, B. Colombo, E. Alessandri, M. Ghio, C. Pizzorni, F. Goegan, M. Cutolo (Genoa, Italy)

PT9A:135
PREDICTORS OF MORBIDITY AND MORTALITY IN PATIENTS WITH EARLY SYSTEMIC SCLEROSIS: LONG-TERM FOLLOW-UP FROM A SINGLE CENTRE INCEPTION COHORT STUDY
S. Panopoulos, V.K. Bournia, G. Konstantonis, K. Fragiadaki, P.P. Sfikakis, M Tektonidoy (Athens, Greece)

PT9A:136
VITAMIN D DEFICIENCY AND GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS. REAL LIFE DATA FROM A REFERRAL CENTER IN NORTHERN GREECE
I. Kostogiou-Anthasaou (1), L. Anthasaou (1), T. Banti (2), M. Gatsiou (2), C. Katsavouni (2), F. Goegan, M. Cutolo (Genoa, Italy)
(1) Athens (Greece), (2) Thessaloniki (Greece)

PT9A:137
OSTEOPROTEGERIN RELATES WITH BIOMARKER THAT HAVE ROLES IN OSTEOPOROSIS, FIBROSIS, AND VASCULO PathY IN SYSTEMIC SCLEROSIS: A POTENTIAL MULTIFACETED RELATIONSHIP BETWEEN OPG/RANKL/TRAIL AND WNT INHIBITOR
A. Taylan, M. Birlik, G. Kenar, B. Toprak, A.R. Sisman (Izmir, Turkey)

PT9A:138
PERIPHERAL BLOOD PERFUSION AND HAND DERMAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro (1), S. Paolini, C. Pizzorni, M. Cutolo, A. Sulli (Genoa, Italy)

PT9A:139
A SIX MONTH FOLLOW-UP STUDY IN RAYNAUD’S PHENOMENON PATIENTS TREATED WITH AMINAPHTONE
B. Ruaro, S. Paolini, C. Pizzorni, M. Cutolo, A. Sulli (Genoa, Italy)
PT9A:141
USE OF BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS (BIVA) FOR THE ASSESSMENT OF BODY COMPOSITION IN A COHORT OF ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Rossi, A. Delta Rossa, A. D’Ascanio, S. Barsotti, S. Bilia, M. Mosca (Pisa, Italy)

PT9A:142
NUTRITIONAL STATUS IN SYSTEMIC SCLEROSIS - A POSSIBLE ADDITIONAL TOOL IN ASSESSING DISEASE SEVERITY AND PROGNOSIS
M. Radić, D. Peric, D. Perkovic, D. Marasovic Krstulovic, K. Boric, D. Martinovic Kaliterna (Split, Croatia)

PT9A:143
QUANTITATIVE COMPUTED TOMOGRAPHY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: FACE AND CONTENT VALIDITY OF AN OPERATOR INDEPENDENT ALGORITHM BASED ON A FREE OPEN SOURCE SOFTWARE
A. Ariani, M. Silva (Parma, Italy)

PT9A:144
IS IT POSSIBLE TO DISCRIMINATE A CLINICAL SUBTYPE OF SYSTEMIC SCLEROSIS ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION?
N. Yudkina, A. Volkov, T. Martynyuk, E. Nikolaeva (Moscow, Russia)

PT9A:145
LUNG INVOLVEMENT PARAMETERS AND CLINICAL CORRELATIONS IN SYSTEMIC SCLEROSIS PATIENTS: A SINGLE CENTRE STUDY
A.C. Trombetta, E. Alessandri, S. Paolino, C. Pizzorni, M. Ghio, B. Ruaro, M. Patanè, E. Gotelli, F. Goegan, A. Sulli, V. Smith, M. Cutolo

PT9A:146
SERUM KLOTHO CONCENTRATION IS INVERSELY ASSOCIATED TO THE SEVERITY OF NAILFOLD CAPILLAROSCOPIC PATTERN IN SYSTEMIC SCLEROSIS PATIENTS
R. Talotta, F. Rigamonti, T. Letizia, S. Bongiovanni, F. Atzeni, T. Vago, P. Sarzi-Puttini

POSTER TOUR 9B
SYSTEMIC SCLEROSIS AND RAYNAUD PHENOMENON
Chair: B. Ruaro (Genoa, Italy)

PT9B:147
A LARGE-SCALE PROTEOMIC APPROACH IDENTIFIED NEW SERUM BIOMARKERS ASSOCIATED WITH SYSTEMIC SCLEROSIS
M. Moroni, M. De Santis, E. Generali, A. Ceribelli, N. Isailovic, M. Caprioli, G.M. Guidelli, C. Selmi

PT9B:148
HOW MUCH TEMPERATURE CAN TRULY IMPACT ON RAYNAUD’S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS?
T. Schioppo, A. Orenti, P. Boracchi, O. De Lucia, A. Murgo, F. Ingegnoli (Milan, Italy)

PT9B:149
HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH TWO DIFFERENT INTRAVENOUS ILOPROST REGIMENS
T. Schioppo, L. Scalone, P. Cozzolino, L. Mantovani, G. Cesana, O. De Lucia, A. Murgo, F. Ingegnoli

PT9B:150
THE D-PRO QUESTIONNAIRE: ASSESSMENT OF THE VITAMIN D STATUS IN SYSTEMIC SCLEROSIS PATIENTS
S. Paolino, V. Tomatis, E. Gotelli, E. Alessandri, M. Patanè, A. Sulli, M. Cutolo (Genoa, Italy)

PT9B:151
NAILFOLD CAPILLAROSCOPY ASPECTS IN UNDIFFERENTIATED CONNECTIVITIES TISSUE DISEASES: RESULTS OF A PRELIMINARY STUDY
B. Neftia, S. Dahou, N. Bidi, F. Mechid, C. Dahou-Makhloufi (Algiers, Algeria)

PT9B:152
DETERMINANTS OF QUALITY OF LIFE IN SYSTEMIC SCLEROSIS AND PATIENT PERCEPTION OF THE DISEASE

PT9B:153
FERTILITY AND PREGNANCY IN SYSTEMIC SCLEROSIS – A EUSTAR CENTER EXPERIENCE

PT9B:154
SCLERONET® A MULTICENTER PILOT PROJECT HEADED BY GILS – GRUPPO ITALIANO LOTTA ALLA SCLERODERMIA
B. Garbagnati, I. Galetti (Milan, Italy)

PT9B:155
FUNCTIONAL STATE OF GASTROINTESTINAL TRACT IN CHILDREN WITH SYSTEMIC SCLEROSIS AND LIMITED SCLERODERMA
I. Chyzheuskaya, L. Belyaeva, K. Khristaleva, H. Kolupaeva, T. Matsushka (Minsk, Belarus)
POSTER TOUR

PT9B:156
MODERN APPROACHES TO REHABILITATION OF CHILDREN WITH JUVENILE SKLEROIDERMA
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, H. Khristaleva, H. Kolupaeva, A. Kolomiets (Minsk, Belarus)

PT9B:157
ILOPROST INDUCED WEIGHT LOST AND MALNUTRITION IN SYSTEMIC SCLEROSIS PATIENT: A CASE REPORT
C. Bruno, S. Naty, L. Abenavoli, R. Grembiale (Catanzaro, Italy)

PT9B:158
FACS CHARACTERIZATION OF CIRCULATING FIBROCYTES FROM LIMITED CUTANEOUS SCLERODERMA PATIENTS
R. Brizzolara, P. Montagna, S. Soldano, A.C. Trombetta, P. Contini, B. Ruoaro, S. Paolino, M. Cutolo (Genoa, Italy)

PT9B:159
SYSTEMIC SCLEROSIS SINE SCLERODERMA
P. Athanassiou, C. Katsavouni, C. Gerodimos (Thessaloniki, Greece)

SCIENTIFIC INFORMATION

ABSTRACT BOOK
All the abstracts submitted and accepted have been published as issue of the Clinical and Experimental Rheumatology Journal, you will be able to collect it at the registration desk. The Abstract Book contains all the Abstracts included all the Lectures and the Scientific Sessions speeches.

GUIDELINES FOR CHAIRPERSONS AND SPEAKERS

Guidelines for chairpersons
• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session
• Respect the timing allowed to the session and to each presentation
• All presentations, discussions and questions must be in English
• English-Italian / Italian-English simultaneous translation will be provided only for the PATIENT SESSIONS

Guidelines for speakers
• Follow the instructions indicated in the paragraph “Audiovisual Instructions”
• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session to meet the chairpersons
• Respect the timing allowed for your presentation
• All presentations, discussions and questions must be in English
• English – Italian / Italian – English simultaneous translation will be provided only for the PATIENT SESSIONS

Audiovisual instructions
In order to optimise the quality of speaker presentations and to avoid possible problems, all speakers are kindly requested to report to the Slide Centre ample time prior to their talk (1 hour) for preview and uploading of their presentation. The optimal format for video projection of presentations is Power Point. Other formats are not foreseen. All meeting rooms include a standard pc workstation at the lectern connected via cable to the Speakers’ Ready Room. The presentations uploaded on the Speakers’ Ready Room pcs are automatically transmitted to the correct meeting room.

Please note the following:
• Conference Center PCs run on Microsoft Office 2013 (Italian language). Please note that presentations in previous editions may not function properly. Files created with other software programs are required to be converted to Microsoft Office 2013.
• Presentations must be on either CD Rom or USB memory key.
• All filmed sequences and/or videos must be in the same Power Point folder and copied into the file before being included in the presentation.
• For films and videos, we recommend ”.avi” and ”mpeg” file extensions. It is also advisable to use common ”codecs”.

In order to optimise the quality of speaker presentations and to avoid possible problems, all speakers are kindly requested to report to the Slide Centre ample time prior to their talk (1 hour) for preview and uploading of their presentation. The optimal format for video projection of presentations is Power Point. Other formats are not foreseen. All meeting rooms include a standard pc workstation at the lectern connected via cable to the Speakers’ Ready Room. The presentations uploaded on the Speakers’ Ready Room pcs are automatically transmitted to the correct meeting room.

Please note the following:
• Conference Center PCs run on Microsoft Office 2013 (Italian language). Please note that presentations in previous editions may not function properly. Files created with other software programs are required to be converted to Microsoft Office 2013.
• Presentations must be on either CD Rom or USB memory key.
• All filmed sequences and/or videos must be in the same Power Point folder and copied into the file before being included in the presentation.
• For films and videos, we recommend ”.avi” and ”mpeg” file extensions. It is also advisable to use common ”codecs”.
EFFECTS OF THE DIET AND THE CLIMATE IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

MEDITERRANEAN CONGRESS OF
SCIENTIFIC INFORMATION
ITALIAN CME - Continuing Medical Education

The Congress has been accredited by the National Commission for Continuing Education with the educational objective:
Clinical Documentation, Clinical Training-Assistance Diagnostics and Rehabilitation, Assistance Profiles - Care Profiles [3], for the following disciplinary areas:
• Medical Surgeon (Disciplines: Rheumatology, Allergology and Clinical Immunology, Anatomic Pathology, Anaesthesia and Reanimation, Clinical Biochemistry, Cardiology, Dermatology and Venereology, Endocrinology, Clinical Pharmacology and Toxicology, Medical Genetics, Geriatrics, Food and Nutritional Hygiene, Respiratory Illnesses, Infectious Diseases, Metabolic Diseases and Diabetes, Sports Medicine, Physical Medicine and Rehabilitation, General Medicine, Internal Medicine, Legal Medicine, Thermal Medicine, Nephrology, Orthopaedics and Traumatology, Clinical Pathology, Paediatrics, Dietetics);
• Biologist;
• Dietician;
• Physiotherapist;
• General Nurses;
• Paediatric Nurse, for nr. 700 participants.
Participants exceeding or with different professions will not be entitled to credits.
Credits will be recognized only upon presence at 90% of the scientific sessions.

Attendance Certificates
ECM certificates will be sent by e-mail after the conclusion of the event previous verification of the requisite of presence and learning.

CME credits: n. 4,2
CME ID 93-218832 – ed.1

ORAL COMMUNICATIONS AND POSTER TOURS
Important notice for Authors: further to the Italian regulations for CME accreditation, please be aware that the Abstracts accepted as Oral communications appear on the Final Scientific Program exclusively with the name of the Presenting Author. However, all the abstracts submitted in an issue of the Clinical and Experimental Rheumatology Journal will be fully published with the names of all the authors. With regard to the accepted Posters they will fully appear with the names of all the Authors on both Final Scientific Program and the issue of the Clinical and Experimental Rheumatology Journal.

Oral Communications
Oral presentations are limited to 8 minutes followed by 2 minutes of discussion. Participants presenting in oral sessions are requested to submit their presentations to the slide centre at least 1 hour before the start of their session.

Poster Exhibition and Poster Tours
Poster Exhibition:
Thursday, April 12th from 16.40 to 17.10
Start the Poster Exhibition in the Poster Area.

Poster Tour:
Friday, April 13th from 12.50 to 14.00
During the lunch break, all presenting authors should stand by their poster board from 12.50 to 14.00 to speak with fellow delegates and poster Chairmen. Nine parallel Poster Tours have been scheduled related to the 9 Topics of Congress.

UEMS AND ITALIAN CME Accreditation
UEMS – European Union of Medical Specialists
An application has been made to the EACCME® for CME accreditation of this event.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at
www.ama-assn.org/go/internationalcme
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Attendance is monitored through a scanner device in order to check learner’s entrance/exit each day [The presence is a main requirement to obtain credits]. Participants will receive their certificate of attendance once they have filled in the evaluation form. All the information will be sent by e-mail after the congress.

Attendance is monitored through scanner devices in order to check learner’s entrance/exit each day [The presence is a main requirement to obtain credits]. Participants will receive their certificate of attendance once they have filled in the evaluation form. All the information will be sent by e-mail after the congress.

UEMS and Italian CME Accreditation

ITALIAN CME - Continuing Medical Education
The Congress has been accredited by the National Commission for Continuing Education with the educational objective:
Clinical Documentation, Clinical Training-Assistance Diagnostics and Rehabilitation, Assistance Profiles - Care Profiles [3], for the following disciplinary areas:
• Medical Surgeon (Disciplines: Rheumatology, Allergology and Clinical Immunology, Anatomic Pathology, Anaesthesia and Reanimation, Clinical Biochemistry, Cardiology, Dermatology and Venereology, Endocrinology, Clinical Pharmacology and Toxicology, Medical Genetics, Geriatrics, Food and Nutritional Hygiene, Respiratory Illnesses, Infectious Diseases, Metabolic Diseases and Diabetes, Sports Medicine, Physical Medicine and Rehabilitation, General Medicine, Internal Medicine, Legal Medicine, Thermal Medicine, Nephrology, Orthopaedics and Traumatology, Clinical Pathology, Paediatrics, Dietetics);
• Biologist;
• Dietician;
• Physiotherapist;
• General Nurses;
• Paediatric Nurse, for nr. 700 participants.
Participants exceeding or with different professions will not be entitled to credits.
Credits will be recognized only upon presence at 90% of the scientific sessions.

Attendance Certificates
ECM certificates will be sent by e-mail after the conclusion of the event previous verification of the requisite of presence and learning.

CME credits: n. 4,2
CME ID 93-218832 – ed.1

CME Provider
AIM Education - Provider n. 93
Via G. Ripamonti, 129
20141 Milan, Italy
Tel. +39 02 56601.1
Fax +39 02 70048585
cme@aimgroup.eu
www.aimeducation.it
GENERAL INFORMATION

CONGRESS VENUE
Porto Antico di Genova - Centro Congressi
Calata Molo Vecchio 15
16128 Genoa - Italy
Tel. +39 010 2485626
www.centrocongressigenova.it

Congress entrance: Foyer Maestrale Module 10
Access to the bench of the Old Dock and the Autosilo
The nearest parking is Autosilo | “Calata Gadda”

HOW TO REACH THE VENUE

FROM AIRPORT
• Taxi: about 15-minute taxi ride
• Bus: 30 minutes with shuttle bus Volabus Euro 6,00
  (stop Piazza De Ferrari).
• Than from Metro De Ferrari Stop / S. Giorgio or 15-minute
  walk, direction Porto Antico.

FROM TRAIN STATION GENOA (Piazza Principe)
• 15-minute walk direction Porto Antico
• Bus: 10 minutes, line 1 or 9, from Marittima Principe F.S. to
  Piazza Caricamento Terminal
• Subway: 5 minutes direction Brignole, San Giorgio Stop

FROM HIGHWAY
Exit from Genoa Ovest and take speed city motorway direction; after 3 km exit at Genoa Porto Antico;
at the end of the road continue 50 m. and turn right at 2nd intersection to access Porto Antico.

CONGRESS CENTRE PARKING
Affordable parking is available in the Porto Antico Area and adjacent to the Conference center.

Discounted parking options:
• Park 1 Molo Vecchio/ Spina Servizi: 90 spots
• Park 1 Calata Gadda: 98 spots
  (additional 57 during holidays)
• Park 2 Autosilo (covered area): 347 spots

Full rate parking options:
Park 1 and 2 – Autosilo and Calata Gadda: €1,80 per hour or fraction

HOW TO USE
(50% discount coupon for Attendees)
To access the two parking indicated above, it is necessary to collect the entry ticket at the entrance bar (to be kept in both cases)
Before leaving, please go to the Secretariat Desk to take your 50% discount coupon: the user must go to the automatic cash desk, or manual, insert the ticket withdrawn at the entrance and the discount coupon, pay the relevant amount and use the ticket issued at the exit bar.
Porto Antico does not allow access and parking for caravans and Campers.
The closest parking area for campers is in Piazza della Vittoria.

FOR INFORMATION:
http://www.centrocongressigenova.it/en/general-info/parking/
## EXHIBITORS

### First Floor

### EXHIBITORS LIST

<table>
<thead>
<tr>
<th>EXHIBITORS LIST</th>
<th>BOOTH NR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>12</td>
</tr>
<tr>
<td>ACTELION PHARMACEUTICALS ITALIA</td>
<td>15</td>
</tr>
<tr>
<td>ADAMO</td>
<td>4</td>
</tr>
<tr>
<td>ALFASIGMA</td>
<td>17</td>
</tr>
<tr>
<td>BRISTOL–MYERS SQUIBB</td>
<td>13</td>
</tr>
<tr>
<td>CELGENE</td>
<td>14</td>
</tr>
<tr>
<td>CESAS MEDICAL</td>
<td>B</td>
</tr>
<tr>
<td>D.S. MEDICA</td>
<td>8-9</td>
</tr>
<tr>
<td>ELI LILLY ITALIA</td>
<td>10</td>
</tr>
<tr>
<td>ERN ReCONNET</td>
<td>C</td>
</tr>
<tr>
<td>EUROIMMUN ITALIA</td>
<td>18</td>
</tr>
<tr>
<td>GRÜNENTHAL ITALIA</td>
<td>5-6</td>
</tr>
<tr>
<td>LABORATORI BALDACCI</td>
<td>11</td>
</tr>
<tr>
<td>MEDITERRANEAN JOURNAL OF RHEUMATOLOGY</td>
<td>A</td>
</tr>
<tr>
<td>MYLAN</td>
<td>1-2-3</td>
</tr>
<tr>
<td>SANOFI GENZYME</td>
<td>16</td>
</tr>
<tr>
<td>SOCIETÀ ITALIANA DI REUMATOLOGIA</td>
<td>7</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

ORGANIZING SECRETARIAT

AIM Group International – Milan Office
Via G. Ripamonti, 129 - 20141 Milan, Italy
Tel. +39 02 566011 - Fax. +39 02 70048578
info@mediterraneanrheuma.com
www.mediterraneanrheuma.com

General information, registration and abstract:
info@mediterraneanrheuma.com

Accommodation:
info.hotel@mediterraneanrheuma.com

OPENING HOURS
The organizing secretariat desk will be at the participants’ disposal at the congress venue according to the following schedule:

- Thursday April 12th, 2018 11.00am-19.00pm
- Friday April 13th, 2018 08.00am-19.00pm
- Saturday April 14th, 2018 08.00am-13.00pm

REGISTRATION INFORMATION

REGISTRATIONS FEES (All fees are 22% VAT included)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegate</td>
<td>€ 530,00</td>
</tr>
<tr>
<td>Students/Trainée*</td>
<td>€ 210,00</td>
</tr>
<tr>
<td>Healthcare Professional**</td>
<td>€ 210,00</td>
</tr>
<tr>
<td>Patients***</td>
<td>€ 50,00</td>
</tr>
<tr>
<td>Young Rheumatologists (under 40) and EMEUNET Members ****</td>
<td>Free Registration</td>
</tr>
</tbody>
</table>

* In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be sent to the organizing secretariat by e-mail or onsite.

** Nurses, physiotherapists and occupational therapists. A letter of confirmation of your status from the Head of Unit or Institute must accompany the formal registration form.

*** For Patient sessions on nutrition and healthcare (Patients, Family members of Patients, Patients Associations members). This fee provides for admission to Patient Sessions to be held on April 13-14 in Libeccio Room. No access to exhibition Area and Scientific Institutional Sessions.

**** Free Registration ONLY for presenters of accepted Abstract belonging to these categories: Young Rheumatologists and Fellows (under 40) and EMEUNET Members.

Free registration must be accompanied with certification issued by affiliated Institution/Department

Registration fees include:

- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance [will be sent by e-mail]
- Access to the exhibition and poster area (no for Patients)
- Coffee breaks and lunch, as indicated in the program
- Abstract Book: issue of the Clinical and Experimental Rheumatology Journal

Payments
Payments onsite are possible in cash (in Euro) or by credit card (American Express, VISA, Euro-card/Master Card). Please note that due to the Italian Law, it is forbidden to transfer cash between different subjects for an amount exceeding € 3,000.00.

Name Changes
After March 12, 2018 sponsors who wish to make name changes will be charged of a handling fee of € 50,00 IVAT 22% included per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.
NETWORKING EVENING
Friday, April 13th, 2018

The Dinner will take place in the beautiful Villa Lo Zerbino in Genoa, on Friday, 13 April 2018 from 8.00 pm

Don’t miss the change to socialize, networking, and get to know your colleagues!

Villa Lo Zerbino

Registration Cost
Each ticket costs € 85,00 starting from an aperitif and followed by a full course dinner, seating around tables and surrounded by the beautiful and antique rooms.

Venue
Villa Lo Zerbino
Passo dello Zerbino, 1 - 16122 Genoa

Parking Information
Villa Lo Zerbino is very close to Piazza Manin, in the high side of the city and well connected to the city center through the large Via Assarotti. Due to the high turnout, we highly recommend to arrange car pooling or to come by taxi as the area does not provide a sufficient number of parking spots and cannot accommodate this need.

Coming by car
From A7-A10-A12-A26, exit Genova Est Distance from Genova Est exit: 2,6 km (8 minutes by car)
Once you’re out of the motorway, stay take the right and proceed straight on Via Bobbio. At the first cross (you can see a traffic light) stay on the right and take Via Montaldo on your right, proceed to the uphill for a couple of kilometers and take your right at the first rotunda. Now you’re in Piazza Manin, turn around the square and proceed stright after the traffic light. Then turn right and you’re in Passo dello Zerbino 1, when you’ll find the entrance of the villa.

Transfer services are not provided for participants.

Call your taxi with Cooperativa RadioTAXI +39 010 5966

SOCIAL MEDIA
Connect with @MediterraneanCongressOfRheumatology on social media.

Be the first to learn about news, important updates, and share your opinions with us.

Our channels are geared towards patients and persons interested in learning more about the effects of the diet and the climate in rheumatic and musculoskeletal diseases.

Follow us on Facebook and Twitter
#RheumaCongress
#MCR2018

@MediterraneanCongressOfRheumatology

Twitter
@RheumaCongress
USEFUL INFORMATION

ADMISSION
Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunch when expected.

What colour is your badge?
Participants: TRANSPARENT
Faculty: RED
Exhibitors: GREEN
Patients and Associations: BLUE

The reissue of the badge will cost €15.00, both in case of forgetfulness and in case of loss.

LANGUAGE
The official language is English.

English-Italian/Italian-English simultaneous translation will be provided only for the PATIENT SESSIONS (Libeccio Room - April 13th-14th)

ATTENDANCE CERTIFICATES
Attendance certificates will be sent by e-mail the last day of the Congress to all regularly registered participants.

Wi-Fi
Free Wi-Fi is available in the Congress area. The network name is Centro_Congressi and each participant will have to enter the password MEDRHEUMA2018.

COFFEE BREAK AND LUNCH
Coffee breaks will be offered in the exhibition area (Exhibition Area, floor 1) as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday</td>
<td>16.40 - 17.10</td>
</tr>
<tr>
<td>Friday</td>
<td>10.50 - 11.20</td>
</tr>
<tr>
<td>Saturday</td>
<td>10.50 - 11.20</td>
</tr>
</tbody>
</table>

A buffet lunch will be offered in the lunch area (Poster Area, Floor 1) as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>13.00 - 14.00</td>
</tr>
</tbody>
</table>

FOOD FOR GOOD
From meetings to solidarity
THIS EVENT DOES NOT WASTE FOOD,
We collect and redistribute surplus food from conferences.
The Congress Centre Porto Antico of Genova, together with Capurro Ricevimenti srl, a catering & banqueting company, is taking part in the FOOD FOR GOOD project launched by Federcongressi & Eventi, in partnership with Banco Alimentare and Equoevento.
A large quantity of food is often left over at the end of conferences, but with the appropriate measures and organisation, this can be distributed to people in need, reducing the event’s production of waste.
The Congress Centre Porto Antico of Genova and Capurro Ricevimenti srl, give this food on an ongoing basis to local charity association.

CLOAKROOM
Cloakroom and luggage storage facilities are available in the congress venue.

INSURANCE
Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.

NO-SMOKING
Smoking in the meeting area is not allowed.

MOBILE PHONES
Delegates are kindly requested to set their mobile phones on silent mode in the halls where scientific sessions are being held.

PRIVACY DISCLOSURE AND PUBLISHING OF IMAGES
Pursuant to article 13 of Legislative Decree no. 196/2003, the personal data of the participants, their videos and photos made during the event, will be used by AIM Italy s.r.l. for purposes related to the communication and the valorization of the event. Such personal data will be communicated only to those people who are in charge of the activities necessary to the aforementioned purposes. Photos and videos will be also published on the website and social networks of AIM Group International (and on the website and social networks of the event, if any).
The treatment will be carried out with appropriate tools ensuring security and confidentiality and may be also carried out by computerized tools that are able to memorize, manage and transmit the personal data.

The data controller is AIM Italy s.r.l., with legal seat in Milan, Via Giuseppe Ripamonti 129, vat no. 00943621003, e-mail address: info.aimcongress@aimgroup.eu.

With regard to the personal data granted, included photos and videos, each participant can exercise the rights set forth in article 7 of Legislative Decree n. 196/2003 by contacting the data controller.

TAXI DISCOUNT RESERVED TO ATTENDEES
An exclusive taxi promotion program is reserved to attendees: members of Cooperativa Radio Taxi Genova apply fixed fares for prearranged routes to and from the conference center.

Routes and Fares
Downtown (€ 12.00)
Train stations Principe and Brignole and all downtown hotels.

Western area (€ 24.00)
Airport, Tower Genova Airport Hotel and all hotels in Genova Sestri and Pegli.

Eastern area (€ 24.00)
AC Hotel and all hotels in Genova Nervi.

Surcharges
Sunday & Public Holiday surcharge: € 2,00
Midnight Surcharge: € 2,50

For information: www.5966.it
Onsite will be a person in charge to call your Taxi!
### FRIDAY April 13th, 2018

#### CONCOMITANTS

**INDUSTRY-SPONSORED Satellite Lectures and Symposia**

**NO CME ACTIVITY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room/Media</th>
<th>Concomitant Industry SATELLITE LECTURE/SYMPOSIUM</th>
<th>Sponsor</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.20-11.50</td>
<td>PLATEA MAESTRALE ROOM</td>
<td>Concomitant Industry SATELLITE LECTURE sponsored by Pfizer</td>
<td>Pfizer</td>
<td>New targets in RA treatment: the case of Janus Kinases inhibition</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speaker: R. Caporali (Pavia, Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.20-11.50</td>
<td>LEVANTE-PONENTE ROOM</td>
<td>Concomitant Industry SATELLITE LECTURE sponsored by Grünenthal</td>
<td>Grünenthal</td>
<td>Gout, a disease of our days: 2018 therapeutical innovations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speaker: L. Punzi (Padua, Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.50-12.50</td>
<td>PLATEA MAESTRALE ROOM</td>
<td>Concomitant Industry SATELLITE SYMPOSIUM sponsored by Actelion Pharmaceuticals</td>
<td>Actelion Pharmaceuticals</td>
<td>PAH_CTD: new insights</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speakers: PAH in rheumatic diseases</td>
<td></td>
<td>M. Matucci Cerinic (Florence, Italy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ESC/ERS PH Guidelines and treatment strategies</td>
<td></td>
<td>M. Palazzini (Bologna, Italy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The GRIPHON Study: CTD subgroup analysis</td>
<td></td>
<td>C. Denton (London, UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs:</td>
<td></td>
<td>M. Cutolo (Genoa, Italy), V. Smith (Ghent, Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Concomitant Industry SATELLITE LECTURE sponsored by Celgene</td>
<td>Celgene</td>
<td>Patient profiling for therapy with Apremilast in psoriartic arthritis</td>
</tr>
<tr>
<td>11.50-12.20</td>
<td>LEVANTE-PONENTE ROOM</td>
<td>Speaker: A. Marchesoni (Milan, Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.20-12.50</td>
<td>LEVANTE-PONENTE ROOM</td>
<td>Concomitant Industry SATELLITE LECTURE sponsored by Sanofi Genzyme</td>
<td>Sanofi Genzyme</td>
<td>IL6: the key of rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speaker: S. Bugatti (Pavia, Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40-17.10</td>
<td>EXHIBITION AREA</td>
<td>MEET THE EXPERT</td>
<td>Grünenthal</td>
<td>Lesinurad - The long awaited innovation in Gout</td>
</tr>
<tr>
<td></td>
<td>BOOTH GRÜNENTHAL</td>
<td>Speaker: P. Richette (Paris, France)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

Gold

Actelion
Bristol-Myers Squibb

Silver

Celgene
Grünenthal
Mylan
Pfizer
Sanofi Genzyme

Supporters

ABBVIE
ADAMO
ALFASIGMA
CESAS MEDICAL
D.S. MEDICA
ELI LILLY ITALIA
EUROIMMUN ITALIA
LABORATORI BALDACCI
MSD ITALIA
SANDOZ